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ABSTRACT

Incorrect inhaled drug delivery technique is a common problem in paediatric asthma
[1-4]. Previously, device technique training has been shown to significantly improve
inhaler skills, using subjective methods, namely check-list analysis [5-8]. However,
more objective measures are needed to examine more comprehensively the effect of
training in preschool children and parents.

Resistance to regular asthma therapy is also a frequent problem when attempting to
treat young children. Reasoning with young children can be very difficult and parents
often have to struggle with their child to achieve compliance [2]. The Funhaler spacer
(FH) (Funhaler™; InfaMed, Australia) has been developed in an attempt to resolve
this issue by incorporating incentive toys to distract the child from the drug delivery
process. Based on parental questiom1aire, the FH has been shown to improve
inhalation technique and increase medication compliance in young children over a
two-week period [1].

A total of 47 children participated in the present study; 24 were randomised to a
standard Aerochamber plus spacer (AC+) (15 male, mean age 63.7 months, range 3090 months), and 23 were randomised to the FH spacer (14 male, mean age 60.5
months, range 36-90 months). Of the 47, four children (AC+: n=2, FH: n=2), with a
mean age of 51 months (36-60 months) were identified as nose breathers, and were
analysed as a separate group. The results from the present study show that repeated
clinic-based technique training had no significant effect on drug delivery (p=O.l51 ).
Furthermore, it was fo~rid that in the clinic setting, children who were using the FH
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spacer were more likely to 'play up' during the drug administration procedure,
compared to children using the AC+ spacer. This was also reflected in the domiciliary
setting, where children who were using the AC+ spacer exhibited significantly higher
drug delivery consistently over the seven days, compared to the FH spacer group
(p=0.032). In addition, the in vitro data showed that drug delivery was significantly
dependent on age, height, weight and breathing parameters (peak inhalation flow,
tidal volume, inhalation volume, exhalation volume, peak exhalation flow) with the
AC+ spacer; however this was not seen with the FH spacer. Although it was expected
that dependence on parameters such as inspiratory volume would affect day-to-day
drug dose, it was found that drug delivery was actually better in the home setting with
the AC+ spacer than the FH spacer. Therefore, these findings suggest that children
interact better with a standard spacer device, such as the AC+, compared to the
incentive FH spacer.
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DEFINITION OF TERMS/ABBREVIATIONS

AC+: Aerochamber Plus® spacer; a commonly used small volume paediatric spacer.

Actuation: Activating the pMDI valve to release a predetermined dose of aerosolised
drug particles.

Andersen Cascade Impactor: An in vitro system designed to measure output and
particle size distribution of aerosolised drugs; consisting of eight stages, a jet stage
and a throat model. Each stage represents a different particle diameter fraction.

Contrivance: Knowing how to use an inhaler/spacer device effectively but choosing
to use it ineffectively.

Device Compliance: Maintenance of correct pMDI-spacer technique by both the
parent and child.

Domiciliary setting: Home setting

FH: Funhaler® spacer, a novel incentive paediatric spacer ~anufactured by InfaMed,
Australia.

Fine Particle Fraction (FPF): The amount of drug available in particles <4. 7 Jlm in
diameter.

Vll

Flow-Volume Simulator (FVS): Replicates human breathing traces by displacing air
according to the breathing parameters of the trace.

Mean Median Aerodynamic Diameter (MMDA): represents the diameter of the
aerosol particles at a cumulative distribution of 50%.

Pressurised metered dose inhaler (pMDI): (drug delivery device) - releases a
predetermined dose of medication in an aerosol form. The drug is suspended in a
propellant and each emitted particle contains the propellant with the drug inside.

pMDI-spacer: Pressurised metered dose inhaler used in combination with a spacer
device.

Pneumotachometer: A device used to measure gas flow by converting differential
pressure to a volumetric flow rate.

Spacer: (drug delivery device) - a holding chamber for aerosolised drug particles;
allows the patient to breathe tidally. Spacers usually have inhalation and exhalation
valves.
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CHAPTERl

INTRODUCTION

1.1 Background to the Study
In order to improve asthma care in the paediatric age group, it is important to isolate
the sources of variability in drug delivery, and implement tactics to improve delivery
of medication. Ineffective drug delivery due to poor inhaler technique is a common
problem in young children. [1-4]; resulting in increased morbidity and greater
number of hospital admissions [5-7]. Previous studies have shown that compliance to
correct inhaler (pressurised metered dose inhaler- pMDI) technique ranges from 3968% [7-11]. Non-compliance is believed to be a result of a combination of factors
such as poor education on asthma and treatment, poor device training, boredom and
apathy [12-14].

The most commonly prescribed delivery system for young children is a pMDI with a
valved holding spacer [2]. Accurate use of a pMDI-spacer is imperative to reduce
dose variability and increase drug delivery into the lungs [15, 16]. Former studies
have not previously assessed the effects of clinic-based technique training by
integrating a qualitative analysis (check-list score) with more objective measures,
such as drug delivery [17-20]. Furthermore, it is not only crucial to assess drug
delivery in a clinical setting, but also outside the clinic, in a more natural setting. The
home provides a more realistic representation of drug delivery, as opposed to the
clinic, where the child's 'best effort' is normally measured.
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Educating patients on asthma and the importance of achieving optimal device
technique can be effective in adults and older children, but is less successful in young
children [12, 19, 21], as these children cannot understand the benefits and needs of
optimal treatment. Moreover, anti-inflammatory drugs do not provide immediate
relief and are often delivered when the child is feeling well (symptom-free days) [2,
22]. Consequently, this may account for the low levels of compliance and
contrivance (knowing how to use the device effectively but choosing to use it
ineffectively) to anti-inflammatory medication [8, 23]. Reasoning with young
children can be very difficult [2], pmiicularly if they are under the age of five [21].
In an effort to address this problem a small volume paediatric incentive spacer
(Funhaler®; InfaMed, Australia) has been developed. The spacer includes a number
of unique features that distract the child from the drug delivery process and provide a
means of self-reinforcing effective inhalation technique (Figure 2.3 p. 25). The
Funhaler® (FH) consists of a toy arm containing a spinning disc and whistle which is
located outside the expiratory valve of the spacer and is activated on exhalation. The
toys perform optimally with deep tidal breathing, encouraging good technique by
requiring the child to inhale deeply to achieve an adequate exhalation to make the
disc spin and whistle sound. This novel device was designed to provide direct
positive reinforcement for children on achieving effective inhalation technique [1].

The FH acts as an incentive for young asthmatics, making the drug delivery
procedure more enjoyable, whilst encouraging optimal inhalation technique,
conducive to effective asthma management. Based on a parental questionnaire, the
FH has been shown to increase device compliance and improve inhalation technique
in preschool children (2-6 years) over a two-week period [1]. A child's interaction
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with the FH (compared to a standard spacer) over a longer period is not known.
Additional evaluation, with more objective measures, is needed to verify if the
previously observed effects of the FH are consistent.

Furthermore, in vitro breathing simulation methods can be used to assess the effects
of inspiratory parameters on drug delivery. The influences of individual breathing
parameters using actual human waveforms have not been previously studied [24, 25].
As variability in children is so large, it is essential to analyse each breath from each
trace separately.

1.2 Significance of the Study
Poor technique and device compliance remams a major problem in paediatric
asthma, resulting in ineffective drug deli very and severe health consequences [ 1-7].
In order to receive the full benefits of therapy, the prescribed dose must be inhaled
into the lungs with each administration [15, 26]. Currently, there are no published
studies examining the effects of pMDI-spacer technique training in young children
and their parents using a measure of drug delivery. Non-compliance to maintaining
proper device/inhalation technique is also a key issue, especially in young children.
The FH spacer was developed in an attempt to increase compliance to optimal
inhalation technique [1].

This study assesses the effect of clinic-based technique training in children and
parents on drug delivery. It also evaluates the way in which children interact with an
incentive device, with prolonged use (three-nine months), and the effect this has on
drug delivery. Lastly, the influence of age, height, weight, spacer design and
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individual breathing parameters are examined on drug delivery using a flow-volume
simulator. Previous studies incorporating breathing simulation methods have
assessed drug delivery using sinusoidal waveforms only; not actual human traces
[24, 25]. This study allows the influence of different breathing parameters to be
examined, by using an in vitro model to simulate actual human breathing traces.

1.3 Purpose of the Study
This study investigates the influence of inhalation technique training, using a pMD Ispacer, on drug delivery to preschool-age children. It also assesses if long-term use
(three-nine months) of an incentive' device (FH spacer) increased device technique
compliance, and improved drug delivery, compared to a standard device
(Aerochamber Plus spacer), in a clinic setting and a domiciliary setting. Finally, the
effects of age, height, weight, spacer design and breathing parameters on drug
delivery are evaluated using in vitro procedures. The results from this study will be
useful in guiding the development of strategies to improve disease management and
the quality of life ofyoung asthmatics.
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1.4 Research Questions
1. Will education and reinforcement of correct device technique in children and their
parents improve drug delivery?

2. Will use of an incentive device (Funhaler spacer) improve inhalation technique
and increase device technique compliance when compared to a standard spacer?

3. Is drug delivery usmg an inhaler and spacer better in a domiciliary setting
compared to a clinical setting where the child is supervised by a health professional?

4. To what extent do breathing parameters, age, height, weight and spacer design
affect drug delivery?

5

1.5 Aims
1. To determine if drug delivery is improved by regular reinforcement of:
-Correct use of the pMDI-spacer by parents
- Optimal inhalation technique by preschool children
- The use of a paediatric incentive spacer

2. To assess intra- and inter-subject variability of drug delivery in a domiciliary

setting in preschool-aged children.

3. To evaluate any differences in drug delivery between a clinical setting, where the
child is supervised by a health professional, and a domiciliary setting where the
'white coat effect' does not exist.

4. To evaluate the effects of:

- Breathing parameters
-Age
-Height
-Weight
- Spacer design
on the efficiency of drug delivery using pMDI -spacers.
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CHAPTER2

LITERATURE REVIEW

2.1 Asthma
2.1.1 Definition
Asthma is characterised as a chronic inflammatory disease of the central and
peripheral airways. Persistently inflamed airways become hyper-responsive [27, 28];
meaning that the smooth muscle around the airway is extremely sensitised, and
exposure to an allergen can trigger an acute episode of coughing, wheezing, chest
tightness and shortness of breath in susceptible individuals [15, 22, 26]. These
episodes are associated with airway obstruction due to constriction and narrowing of
the bronchioles, excessive mucus secretion and accumulation, and increased
inflammation in the lining of the airways. If asthma is not well controlled, symptoms
are recurrent and exacerbated at night, early in the morning, during exercise and
when exposed to certain aeroallergens such as dust mites, animal dander, moulds,
pollen and air pollution [4, 27, 28].

2.1.2 Airway Inflammation and Remodelling
Asthma is an inflammatory disease of the airways [27, 29, 30]. This inflammatory
response occurs due to the interaction between an allergen and an IgE antibody
bound on the surface of a mast cell. When the allergen binds to the IgE antibody
(antigen-antibody interaction) the mast cell is activated and starts to release
histamine and · leukotrienes, causing smooth muscle contraction, and increased
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vascular permeability and mucus secretion in the bronchioles of the airways [26, 31].
This response is immediate and starts the inflammatory cascade by attracting other
inflammatory cells such as eosinophils, neutrophils and basophils to the site, which
release more potent inflammatory mediators and directly contribute to the overall
inflammation of the bronchial mucosa. This is called the late phase response and the
process occurs within two hours to a few days [31]. The persistent inflammation
sensitises and disrupts the lining of the airways causing airway hyper-responsiveness
[27, 28].

Along with inflammation, structural changes of the airways, referred to as airway
remodelling, occur in all patients with asthma. It is not yet known whether
inflammation and remodelling occur independently or if inflammation is a result or
cause of airway remodelling [28, 32-34]. Airway remodelling consists of smooth
muscle hyperplasia and hypertrophy, sub-epithelial fibrosis, mucous and goblet cell
hyperplasia, and epithelial detachment and regeneration. Collectively, these
structural alterations cause thickening of the airway walls and are thought to be
responsible for airway obstruction and hyper-responsiveness [35].

2.1.3 Diagnosis
Asthma is diagnosed on the basis of family history of asthma or other atopic
diseases, and by recognition of one or more clinical symptoms such as coughing,
wheezing, chest tightness, and dyspnoea [3 6]. When a dramatic and apparent
response to corticosteroids is seen a patient is said to have asthma [23]. Although
most patients respond positively to inhaled and systemic corticosteroids, there is
however a sub-group of patients with 'difficult to control asthma' who are
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corticosteroid resistant. These patients respond poorly to high doses of systemic
corticosteroids, therefore to reduce serious side-effects early detection of
corticosteroid resistance is crucial. Studies suggest that insensitive patients may fail
to convert the steroid to an active form, may rapidly eliminate the steroid, may have
incomplete glucocorticoid absorption or a reduction in glucocorticoid receptor ligand
and DNA binding affinity due to uncontrolled immune activation, possibly triggered
by allergens or infections [3 7, 38].

Three asthma phenotypes have been identified in children: transient wheeze which
resolves by age three, non-atopic wheeze in toddlers, and atopic wheeze where 80%
of cases begin after six years of age [39]. If severe asthma symptoms are experienced
during childhood it is probable that symptoms will persist into adulthood.
Conversely, in cases of mild childhood asthma, wheezing and other symptoms are
likely to subside before adulthood [36, 40]. Some studies propose that if asthma is
diagnosed early in life and if treatment is initiated before six years of age, persistent
changes in lung function may be minimised [36, 41]. However, there is some conflict
of opinion and more research is needed in this area [42].

2.1.4 Risk Factors for Asthma

2.1.4.1 Genetics
Previous literature has shown that there is a significant genetic component associated
with the development of asthma [43, 44]. A study conducted in Northern Sweden
revealed that a person with a family history of asthma has a 3-4 fold greater risk of
developing asthma compared to someone with no genetic history of asthma [45].
Other studies have documented that the genetic contribution to childhood asthma can
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be as high as 75% [46, 47]. Analysis of family pedigree patterns have been shown to
best fit with models of polygenetic or oligo genetic inheritance types, indicating that
multiple genes may be involved in determining an individual's susceptibility to
asthma [48].

2.1.4.2 Tobacco Smoke
An active smoker has a significantly higher risk of developing asthma as an adult. A
study conducted in Northern Sweden documented that current or ex-smokers with a
family history of asthma have a 7-fold risk of acquiring asthma when compared to
people who have never smoked and have no family history of asthma [49]. Exposure
to tobacco smoke in utero alters the development ofthe foetal immune system which
may predispose children to allergic diseases such as asthma [50]. In addition, tobacco
smoke exposure during foetal growth and early childhood has been shown to
significantly impair lung growth and lung function [51-53]. A meta-analysis study
evaluating the influence of tobacco smoke exposure on the development of childhood
asthma found that there was a greater risk of acquiring asthma if the parents were
smokers [54].

2.1. 4. 3 Diet/Nutrition
Changes in diet and eating habits may account for the increased rates in asthma cases
over the last couple of decades. A current meta-analysis of 12 studies concluded that
high body weight among school aged children increased the risk of developing
asthma by approximately 50%. The effect of high birth weight was less distinct but
still significant [55]. Other studies have found that children in industrialised
countries, who consumed high levels of polyunsaturated fats and processed foods,
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had an increased risk of developing asthma; low intake of antioxidants and fresh
fruits was also associated with an increased risk [56, 57]. A study involving
asthmatic children between six to seven years of age showed that an increased
consumption of fruits and vegetables daily provided a protective effect against
wheezing, whereas large consumption of bread, butter and margarine increased
asthma symptoms [57, 58].

2.1.4.4 Allergen Exposure

There is increasing evidence to suggest that exposure to high levels of indoor dust
mite allergen is an important risk factor for the development of atopic sensitisation in
children, which may facilitate the development of allergic respiratory disease [5961]. A large prospective study following children from birth to seven years of age
found that high exposure to house dust mite and cat allergen significantly increased
the development of atopic sensitisation in the first three years after birth and up to
seven years of age. Children with a family history of atopy were much more
susceptible to asthma with even very low levels of exposure [62]. Conversely, more
recent studies have shown that endotoxin exposure during infancy can provide a
beneficial guard against allergen sensitization by enhancing type 1 immunity, and
thus reducing the risk of allergic airway disease such as asthma [63-65].

2.1.5 Prevalence
Despite increased knowledge of the pathophysiology of asthma, and advances in
treat~nent

over the past several years, asthma still remains a major health issue in

today's society [26, 66]. Asthma affects 300 million people world wide and is the
cause of 1 in every 250 deaths worldwide [27]. Globally, the frequency of asthma is
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greater in industrialised Western countries (i.e. Australia, New Zealand, UK) than in
developing countries with a large rural population (i.e. Eastern Europe, India, Africa)
[48, 67, 68]. In addition, data collected in industrialised countries over the last 40
years has shown a significant increase in the prevalence of childhood asthma [48].

A study conducted in 2001 found that Australia has the highest prevalence of asthma
in pre-school children, compared to other industrialised countries such as the UK,
Canada and USA [56]. The incidence of asthma in Australia is third highest in the
world [69, 70] and is continually rising amongst Australian-born children [71]. In a
national health survey, parents reported asthma as the biggest health issue affecting
their children [72].

2.1.6 Impact of Asthma
Asthma can have a dramatic impact on the affected individual, their family and
health services when the condition is not well managed. Poor symptom control leads
to increased emergency department (ED) visits and hospitalisations, lost educational
experiences due to school or work absence, sleep disturbance, inability to interact in
sporting events and an overall lower quality oflife [27]. Stanford and colleagues [73]
reported that the cost of paediatric asthma related ED visits and hospitalisations in
1997 were approximately $157 million and $669 million respectively; these expenses
are likely to have increased due to the rise in prevalence rates and cost of asthma
medication. A survey conducted in New South Wales in 2001 revealed that 16% of
children (2-12 years old) had visited an ED for an acute asthma episode over the past
year [74]. Previous literature has also shown that children 0-4 years of age have the
highest rates of ED attendance and hospital admissions in Australia as a result of
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poor asthma management [69, 75]. In addition, a survey comparing a cohort of
asthmatic and non-asthmatic children documented that overall expenditure for
asthmatic children was 2.8 times higher than for non-asthmatic children [76].

It is very difficult to measure the burden of lost oppmiunities (i.e. decreased social

activity, missed work/school days) for asthmatic people and their families.
Collectively, people with asthma have over 100 million days of limited activity
annually due to chronic symptoms [28]. A 2001 New South Wales health survey
reported that 58% of children with asthma aged between 2-12 years could not
perform normal daily activities to a 'satisfactory level in the last 12 months [74]. A
study conducted in the United States examined the effects of sleep deprivation due to
night time symptoms, and found that nocturnal disturbance and school absenteeism
were closely associated. The study reported that 40% of children had experienced
nocturnal symptoms in the previous month. During the same period, 35% of children
were absent from school and 36% of parents reported that their child's educational
performance decreased due to their asthma. The study also showed that if the child's
sleep was disturbed one to three times in a month, 44% of parents missed work and if
nocturnal wheezing had occurred on seven nights in the month, 56% missed work
[77].

2.2 Asthma Treatment and Therapy
2.2.1 Asthma Triggers
An important aspect of treatment and symptom control is to identify specific triggers
which exacerbate asthma symptoms. Asthma triggers can be identified through
allergy testing. Patients should avoid exposure to these allergens by implementing
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lifestyle and environmental changes. For example, individuals allergic to animal
dander should remove pets from the house, and individuals with dust mite allergies
should clean their mattresses, pillows and carpets regularly to reduce exposure [59,
78]. However, a study of house dust mite prevention measures has shown that such
precautions do not effectively reduce levels of exposure, and that susceptible people
are still at risk [79]. Therefore, asthma medication must be available.

2.2.2 Medication
When administered correctly, effective asthma therapy is able to control the
pathophysiological processes of asthma in most patients by reversing airway
obstruction and managing airway inflammation [80]. The most commonly used
medications to treat asthma include short-acting beta2 agonists, long-acting beta2
agonists and anti-inflammatory drugs (preventer medication) [27, 28].

2.2.2.1 Beta2Agonists
Short-acting beta2 agonists such as salbutamol, more commonly known as
Vento lin®, work by enhancing bronchodilation. These medications, also referred to
as 'rescue drugs', provide immediate relief of acute asthma symptoms by binding to
the beta2 receptors on the smooth muscles of the bronchioles, causing them to relax
and dilate. Symptom relief lasts up to three to four hours [4, 81, 82]. Short-acting
beta2 agonists should only be used to relieve acute symptoms, and if required more
than three times a week, anti-inflammatory therapy should be commenced. Longacting beta2 agonists such as salmeterol (Serevent®) enhance bronchodilation over a
longer period of time. These drugs last up to 12 hours after administration and are
used in conjunction whh preventer/anti-inflammatory medications [4, 82].

14

2.2.2.2 Corticosteroids
Long-term therapy for chronic asthma should not be based only on 'rescue'
medication and symptom relief. Airway inflammation is the primary cause of asthma
symptoms, thus treatment should be focused on suppressing the inflammation with
anti-inflammatory medications and normalising lung function. With this aim, day-today asthma symptoms will be reduced and a better quality of life will be obtained
[82-84]. Prophylactic anti-inflammatory/preventer medications can include both oral
and inhaled corticosteroids (ICS). Oral corticosteroids have generally been replaced
with ICS in most cases of asthma; however, they are still used in situations of acute
asthma exacerbations where the patient is not responding to beta2 agonists [22].

Corticosteroids are the most potent and effective form of anti-inflammatory
medications used to treat chronic asthma [83, 85]. Corticosteroids work by imitating
the action of natural hormones produced by the adrenal cortex that are involved in
regulating airway inflammation. These steroid hormones act on many cell types,
which accounts for both their localised therapeutic effects, and unwanted systemic
effects. Corticosteroids pass through the plasma membrane of cells and bind to the
corticosteroid receptor in the nucleus, forming a corticosteroid-receptor complex.
This complex can activate transcription factors or directly bind to specific DNA sites
and alter gene expression. Through these mechanisms cmticosteroids block active
sites of proinflammatory genes at the molecular level and regulate the release of
molecules involved in an inflammation response at the cellular level [85-87].
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2.2.2.3 Inhaled Corticosteroids

Long-term use of res has been proven to reduce airway inflammation and bronchial
hyper-responsiveness, thereby decreasing exacerbations and the need for rescue
drugs. [22, 88, 89]. Furthermore, it has been shown that

res

provide a protective

effect in children and significantly reduce the risk of asthma-related hospitalisations
and ED visits [90]. Commonly used ICS include: budesonide, beclomethasone
dipropionate (BDP), triamcinolone, flunisolide and fluticasone propionate (FP) [88].
The different ICS drugs vary greatly in terms of topical activity and adverse local
and systemic side effects [15, 22]. FP has the benefit of an extensive first-pass
hepatic metabolism, which means it has a low oral bioavailability (<1 %) [86, 89, 91]
and any drug deposited in the gastrointestinal tract is inactivated by the liver [22].

A new inhaled corticosteroid drug, ciclesonide (CIC), has been approved in many
countries for use in adults and children over four years of age [2]. This novel drug
has been designed as a 'soft steroid drug', which means it achieves high local
concentrations to the target area with limited systemic exposure and adverse side
effects [92].

ere

is inhaled as an inactive complex and is metabolised to its active

form in the airways [84, 93]. Once activated,

ere

exerts high localised anti-

inflammatory activity in the lungs, and is then rapidly metabolised and inactivated
[92]. In addition to these pharmacokinetic benefits, CIC has a low oral bioavailability
(1 %) and a high degree of protein binding (99%), reducing systemic activity and

making it, at present, the safest res drug [84, 93, 94].
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2. 2. 2. 4 Adverse Systemic Side Effects with Inhaled Corticosteroids

Although administering corticosteroids via inhalation is associated with fewer
systemic side-effects compared to oral administration, the risks of adverse sideeffects are still significant with high doses of res. Thus, to reduce unwanted sideeffects the minimum effective dose for optimal symptom management should be
used, and the amount of drug particles inhaled into the bronchiole tree of the lungs
maximised [28, 87, 95]. Local adverse effects in both adults and children can include
dysphonia and oropharyngeal candidiasis due to oral deposition of drug particles.
These effects can be minimised by implementing good oral hygiene (mouth rinsing
and gargling) after use. Other adverse side-effects include adrenal suppression and
depletion ofbone mineral density [4, 22, 88, 93].

In pre-pubertal children the most concerning side-effect associated with long-term
use of res is the impact on bone turn-over and growth. The effects on bone turn-over
include inhibition of new bone formation and bone reabsorption. These adverse
effects are especially troubling in children, who are acquiring bone mass quickly [4,
88]. However, studies examining the effects of moderate

res

use (doses less than

400 11g/day of FP or equivalent) on bone turn-over have not found a detrimental
effect [4, 96].

Long-term follow-up studies have shown that growth during childhood can be
suppressed with

res

use, however, this effect is short-term, and after the initial

impact subsequent growth and final adult height are normal [4, 97-100]. Long-term
therapy with doses of up to 200

~-tg/day

of FP or equivalent in children is considered

to be safe, with limited risk of adverse effects. The dose response curve for
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fluticasone propionate starts to plateau with doses above 500!-Lg/day, and at this point
the danger of systemic side-effects is greater [88]. The risks associated with undertreated asthma can be far greater than the risks associated with ICS use. Studies have
shown that poor asthma management can affect final adult height severely, as well as
cause lung hyper-expansion which can lead to significant chest deformities [1 00102].

2.2.3 Delivery Devices
The delivery system is a vital aspect of treatment [5]. Inhalation therapy is the
preferred and recommended alternative to oral drug administration for both adults
and children. Inhaled aerosol medications deliver the drug directly to the affected site
(airways); this results in a rapid therapeutic response, with a lower drug dose
required and less systemic side effects [9, 27, 103]. There are currently three main
types of inhalational delivery devices for children: dry powder inhalers (DPis),
nebulisers, and pressurised metered dose inhalers (pMDis) with or without an
attached spacer [4, 9, 104].

DPis

are

inspiratory-flow driven

[22]

and

do

not reqmre

hand-mouth

synchronisation. However, the disadvantage of DPis is that the emitted drug dose is
dependent on the inspiratory flow of the patient. A low inspiratory flow causes the
drug particles to impact in the mouth and throat, and as a result the lung dose is
reduced and systemic side effects are increased [1 05]. The inspiratory force required
to receive an appropriate dose from a DPI is generally difficult to achieve for
children under eight years, making these devices unsuitable for children below this
age group [2, 4, 9].
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The two other inhaler devices, nebulisers (Figure 2.1) and pMDis with a valved
holding spacer, are suitable for preschool-age children and do not require
synchronising inhalation with the release of drug [1 06, 107]. The pMDI-spacer
combination is more commonly used in this age group as nebulisers are expensive,
difficult to operate, may need an external power source, are time consuming (each
treatment session takes up to 10-15 minutes) and less convenient [82, 106, 108-11 0] .

Figure 2.1: A nebuliser with a face mask for drug inhalation and a pump
for drug aerosolisation.

In addition, up to 90% of the medication can be lost to the environment if the child's

inspiratory flow does not exceed the driving flow ofthe nebuliser [109, 111]. Studies
have also shown that nebulisers significantly increase the heart rate after treatment
when compared to pMDis [106, 112-114], suggesting that there are greater adverse
side-effects associated with nebulisation [115]. Furthermore, it has been shown that
nebulisers require a much larger loading dose than pMDis to achieve the same
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intrapulmonary delivery [91, 106, 112]. It is estimated that 2000 [lg ofFP is needed
via a nebuliser to achieve the same effect as 300 [.tg ofFP via a pMDI [91].

pMDis are relatively inexpensive, portable, convenient and require less time to use
than nebulisers [106, 112, 113]. The main problem with the use ofpMDis in children
under the age of six years is the difficulty of synchronising inhalation with actuation
(compressing pMDI to release drug) [22, 106]. However, this can be overcome with
the use of a spacer device, which is placed in between the pMDI and child's mouth
(Figure 2.2). A spacer provides a reservoir for the medication from which the child
can breathe tidally, making synchroi1isation less important [104, 116]. Fmihermore,
spacers decrease the velocity of the emitted aerosol before it enters the mouth, and
allow the propellant around the drug to evaporate so that the inhaled particles are
smaller and diffuse further into the lungs with decreased oropharyngeal impact [22,
82, 104, 106, 111, 116].

Young children using a pMDI-spacer may need to take several breaths to clear the
drug from the spacer [117, 118]; when larger spacers are used, the time taken to
empty the drug from the spacer increases. Therefore, small volume spacers are the
best option when treating young children, as they allow the drug to be inhaled from
the spacer in a more concentrated form [116, 117, 119] before the particles
agglomerate and are lost due to sedimentation [2].
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Figure 2.2: A child using a pMDI with an Aerochamber Plus® spacer.

One of the problems with plastic spacers is that they can become electrostatically
charged on the inside, causing the drug particles to adhere to the spacer wall, and
thus compromising drug output [116, 120]. However, this problem can be overcome
by coating the inside of the spacer with ionic detergent [118]. Detergent coating of
spacers has been shown to significantly reduce electrostatic charge and increase drug
delivery by up to 46-71% [121].

2.3 Factors Affecting Drug Delivery
2.3.1 Age, Height and Ventilatory Parameters
There are many factors which affect drug delivery in children, including age, height
and breathing parameters such as tidal volume, peak inspiratory flow and inspiratory
volume [116, 119, 122].

2. 3.1.1 Breathing Simulation
The influence of age, height, weight and breathing parameters on drug delivery can
be studied in vitro using a flow-volume simulator (FVS). Pre-recorded human
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breathing traces can be simulated through a flow-volume simulator to replicate the
patient's actual breathing pattern. The delivered dose of drug that would have been
inhaled by the patient is captured on an inspiratory filter inserted between the drug
delivery device (pMDI-spacer) and the breathing simulator [123]. While in vivo filter
data can be correlated with markers of increasing lung size (age, height, and weight)
the FVS can be utilised to examine the effects of individual inspiratory parameters,
for example lag time, inspiratory volume and inspiratory flow.

Previous studies using breathing simulation methods have incorporated sinusoidal
and square waveforms instead of aCtual human patterns. Investigators have created
sine and square waveforms using the average measure for each breathing parameter
(tidal volume, peak inspiratory flow, breathing frequency and inspiratory duty cycle)
from several regular breathing traces [24, 25]. This method of investigation reduces
the variability which is found from breath to breath and patient to patient, especially
in children. As intra- and inter-variability is high in children it is vital to incorporate
the actual trace for each patient and analyse each breath separately.

2.3 .2 Technique, Training and Education
Incorrect use of inhaler devices significantly compromises drug delivery and
increases adverse side-effects [5-7]. In order to achieve the full benefits of treatment,
competent administration is essential [15, 26, 124]. Incorrect pMDI technique is
common among many patients, including adults [125-128], but especially young
chndren [129, 130]. Therefore, training and technique assessment by a health
professional is crucial [5, 6, 19, 20, 125]. A study of 55 asthmatic children showed
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that only 73% had a near correct technique that allowed any drug to enter the lungs
[7].
In young children, the parent is responsible for administering the medication [ 131];
therefore the parent must be taught how to use the device correctly, and the child
how to perform the optimal breathing manoeuvre [21]. The most common errors
parents make when administering inhaled therapy include: not shaking the pMDI
canister before actuating, not allowing five breaths to be completed before reactuating and not co-ordinating actuation with the start of inhalation. Errors made by
young children include: failure to keep their mouth tight over the mouthpiece of the
spacer to stop the drug from escaping, inability to inhale the drug slowly and deeply
to minimise impaction of particles in the proximal airways, breathing from the nose
instead of the mouth, and forgetting to breath-hold after inhalation to maximise
sedimentation of particles [103, 129, 132]. Previous studies suggest that the most
beneficial form of education for adults and older children is one which includes both
verbal counselling and a physical demonstration [133]; written instructions alone are
not an effective measure [134, 135]. Toddlers learn by imitation and repetition,
therefore video demonstrations or role-playing situations can be effective teaching
methods [18].

Caregivers and patients who receive repeated training sessions are more likely to
display competency in device implementation technique when compared to patients
with no training [18, 19]. Kamps and colleagues [18] demonstrated that only 57% of
children had correct technique after one training session and 98% after three
sessions. In order to ensure the device is continually used effectively, monitoring and
reinforcement is needed [19, 135, 136]. A previous study found that after patients
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had established effective skills, only half continued to use the pMDI effectively in
the 1-30 days following the official training session [137].
Contrivance (knowing how to use the device effectively but choosing to use it
ineffectively) is also a problem in paediatric asthma [8, 23]. Education and strong
communication between the physician and parent/guardian is a crucial determinant
of therapeutic success [22, 131, 138, 139]. If the parent does not see their child's
asthma as a severe health problem due to lack of knowledge about the condition, it is
likely that device compliance will be poor [28, 140, 141]. The aim of healthcare
providers is to impart the importance of correct device teclmique, and continuous
anti-inflammatory treatment, in order to attain better asthma control, reduce
exacerbations and reduce the need for aggressive interventions [28, 142]. Education
is an integral pmi of asthma management as it provides patients and their families
with a greater understanding of asthma, device implementation skills (and the
impmiance of device compliance), and emergency behaviours, leading to better
symptom control and thus reducing associated morbidity [28, 143]. However, whilst
education is an effective method for increasing co-operation in older children and
parents, it is not so effective in young children, particularly if they are under the age
of five where reasoning can be very difficult [12, 19, 21].

2.3 .3 Device Compliance
In an attempt to address the issue of device technique compliance in young asthmatic
children, an incentive spacer, the "Funhaler" (Funhaler®; InfaMed, Australia), has
beeri developed (Figure 2.3). The spacer features a toy arm with a disc and whistle,
so that when the child breathes deeply the disc spins and a whistle sound is created.
The incentive toy encourages good technique (deep tidal breathing) and does not
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interfere with delivery of medication, as it is separated from the main inspiratory
route. The Funhaler (FH) is designed to address the needs of young asthmatic
patients by making the delivery process more enjoyable and less boring in an attempt
to increase device technique compliance. A two week preliminary study, based on a
parental questionnaire, revealed that compliance in children (2-6 years of age)
increased with the FH when compared to a standard spacer. However, the long-term
effects of such an incentive device are not yet known [ 1] .

Figure 2.3: Funhaler Spacer®. A: Parts of the Funhaler spacer. B: A 4-year-old
child using the Funhaler spacer with a face mask.

2.4 Conclusion
From the review of literature it is apparent that there are many factors that can
influence drug delivery in young children; incorrect inhaler technique, the child's
breathing parameters, contrivance and device compliance. The effect of inhaler
technique training in preschool children (2-6 years) and their parents has not been
extensively examined before. Previous studies have found that training improves

.·.
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technique, however their results have been based on subjective measures, namely
check-list analysis [17-19, 135]. Therefore, more objective methods of assessment
are needed to conclusively evaluate the effects of inhaler training. Furthermore, the
effect of clinic-based technique training on drug delivery in the home has not been
examined. The home provides a more realistic representation of drug delivery as
there is no clinical supervision and the child is in a more comfortable environment.
Therefore, in addition to clinic-based training, this project assesses drug delivery in
the home.

A preliminary study, based on a parental questionnaire, has indicated that the
Funhaler® design improves device technique compliance in pre-school aged children
(2-6 years) over short-term (two week) use [1]. This project examines the long-tern
effects of the FH, with more objective measures, on the common problem of device
compliance.
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CHAPTER3

MATERIALS AND METHODS

3.1 Materials
3 .1.1 Chemicals/Drugs
Methanol (Lab-Scan HPLC grade)
Sodium Hydroxide (NaOH) (Sigma, USA)
Liquid salbutamol Chemical Reference Standard (Glaxo, USA)
Salbutamol pMDI (1 001Jg/actuation, Vento lin®)

3 .1.2 Equipment
Inspiratory Filters (Hydrophobic membrane Uni-Filter Junior Datex-Ohmeda)
Aerochamber Plus Spacer® (AC+; Trudell Medical International, Canada, 135ml)
Funhaler Spacer® (FH; InfaMed, Australia, 225 ml)
Flow-Volume Simulator (Series 1120 Hans Rudolph, Kansas, USA)
Pneumotachometer (RSS 100 Hans Rudolph, Kansas, USA)
UV Spectrophotometer (UV -1601, Shimadzu Scientific, Japan)
Bu~hner

flask

Reticulated vacuum/suction system
Digital Video Camera (Canon 2.0 Mega Pixels MVX3i)
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Flow Chamber Perspex Box
lL Calibration Syringe (Koko, Pulmonary Data Service Instrumentation)
Andersen Cascade Impactor (ACI; Andersen Instruments, USA)
Vitalograph (Model DFM2, Copley Scientific, UK)

3.2 Study Population

Ethical approval for this study was obtained from Princess Margaret Hospital Ethics
Committee (Registration No. 933/EP) and the Human Ethics Sub-Committee Faculty
of Computing Health and Science, Edith Cowan University, Joondalup.

The study involved a cohort of 47 children between 2.5-7.5 years of age with mild,
stable asthma who were on daily inhaled anti-inflammatory medication (fluticasone
propionate) and did not suffer from any other lung disorders. The 47 patients were
recruited from a larger trial (Funhaler Trial) which is cunently being undertaken at
Princess Margaret Hospital for Children in Perth, Australia. The trial involves
monitoring asthma symptoms and compliance therapy in children using either an
Aerochamber Plus

®

(AC+; Trudell Medical International, Canada) or a Funhaler

®

(FH; InfaMed, Australia) spacer device, over a 12 month period. Of the 47 patients in
the present study, 24 were part of the AC+ spacer group (15 male, mean age 63.7
months, range 30-90 months), and 23 were part of the FH (14 male, mean age 60.5
months, range 36-90 months). Four children (AC+: n=2, FH: n=2), with a mean age
of 51 months (36-60 months) were identified as nose breathers. These children were
analysed as a separate group. All patients had used either the AC+ or FH for a period
of three to nine months (depending on the number of visits they had previously
attended for the. }{unhaler Trial). The participants' parents or caregivers were
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provided with both verbal and written information regarding the study on their
regular attendance for the Funhaler Trial. Parents were assured they were free to
refuse participation or withdraw their child from the study without prejudice to future
asthma care. On agreement to take part in the study parents were asked to sign an
informed consent (Appendix I p. 87) on their child's behalf.

3.3 Study Design
The present project was divided into three categories: clinic visit, domiciliary filter
study and in vitro procedures (Figure 3.1 ).

3.3 .1 Clinic Visit
3.3.1.1 Spacer Technique Evaluation and Training

Initially parents and children attended a clinic visit where two filter studies were
performed. The first study involved a pre-training filter analysis. The parent was
asked to administer five single actuations of pMDI salbutamol

(100~-Lg/actuation,

Ventolin®) while the child breathed for five tidal breaths in between each actuation,
using the technique normally employed at home. Each child used the spacer he/she
was randomised to. Salbutamol was captured on a low resistance inspiratory filter
(Uni-Filter Junior Datex-Ohmeda) with a minimum dead volume (<50ml), which
was placed between the child's mouth and their spacer (Figure 3.2 & 3.3). The
aerosol was drawn onto the filter- the child did not inhale any drug into their body.
Both the parent and child were video-recorded (using a digital camera which was
connected to a desk top computer containing a multi media software program) in
their attempt to use the device optimally. As part of the clinic training process, the
technique

employe~

by both the parent and child was assessed according to a
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criterion checklist (pre-training evaluation; Appendix II p. 91), and any errors in the
parent's administration technique and the child's inspiration technique were
corrected by physical demonstration and verbal instructions.

The number of training sessions the parent and child had received prior to their clinic
visit for the present study was dependent on the number of visits they had previously
attended for the Funhaler Trial. Children who were recruited at visits one, two and
three had received one, two or three training sessions, respectively, before
recruitment into this sub-study.
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CLINIC VISIT

DOMICILIARY

>-

Pre-training filter study

>-

Performed in the child's home
with no study supervisor

>-

Evaluation of administration
procedure and technique training
(both parent and child)

>-

Administration and filter set-up
was identical to the clinic filter
studies

>-

A new filter will be used every
morning and evening

>-

Filters were collected at the end
of the 1 week period from the
child's home

>-

Post-training filter study

>-

Breathing trace recorded (for in
vitro evaluation)

>-

Domiciliary materials provided

Analysis of drug delivery on pre and post
training filters (2 samples collected per
child):
evaluation
of
the
effects
administration technique training on drug
delivery in a clinical setting.

Analysis of drug delivery over a 1 week
period (morning and evening- 14
samples collected per child): evaluation
of variability in drug delivery in a home
setting.

D
IN VITRO METHODS

>-

Breathing pattern transferred to a
FVS

);>

Filter placed between FVS and spacer
device (FVS represents child in vitro)

);>

Administration procedure mimicked
the clinic and domiciliary filter
studies

);>

All measurements were taken in
duplicates

);>

Measurement of breathing parameters

Analysis of drug delivery using a FVS:
evaluation of the effects of age, height, weight
and breathing parameters on drug delivery.

Figure 3.1: Study design. The project was conducted m three areas: clinic visit,
domiciliary filter study and in vitro procedures.
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Figure 3.2: Funhaler spacer attached to a filter. Aerosolised drug is collected on the
inspiratory filter, so the child does not inhale any drug.

Figure 3.3: Aerochamber Plus spacer attached to a filter with an adaptor.
Aerosolised drug is collect on the inspiratory filter, so the child does not inhale any
drug.
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Subsequently, both the parent and child were asked to watch a one minute
educational video featuring either the FH or AC+ spacer, depending on which device
the child was randomised to. The FH children did not see the AC+ video and vice
versa, however, both videos showed the same caregiver administering medication
and the same child performing the breathing manoeuvre. The video demonstrated the
optimal breathing technique to be performed by the child (deep slow breathing, five
tidal breaths after each actuation) and correct use of a pMDI-spacer by the parent
(shaking. the canister before each actuation, allowing five tidal breaths before reactuating). The video also contained information on how to clean the spacer and
reduce electrostatic charge by detergent coating. Once the training session was
completed a post-training filter analysis was conducted. The same administration
procedure was performed as with the pre-training filter study. The parents and
children were video-recorded again and their technique was re-assessed (posttraining evaluation; Appendix II p. 91). The effects of training were analysed by
comparison of the pre- and post-training videos and technique scores (qualitatively)
and the total drug recovered on the pre- and post-inspiratory filters (quantitatively;
see section 3.4.1 pg. 44).

3.3.1.2 Breathing Recording

Breathing patterns were recorded for all study subjects during the clinic visit using a
custom-built transparent flow chamber consisting of a Perspex box and a paediatric
pneumotachometer (RSS 100 Hans Rudolph, Kansas, USA). The flow chamber
enclosed a small volume spacer and a pMDI (Figure 3.4). These devices were held in
position by a special sleeve fitting located on the floor of the box. The front of the
Perspex box contained an opening allowing only the mouthpiece of the spacer to
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protrude whilst keeping the exhalation valves of the spacer inside the box. The roof
and the side of the box also contained small openings. The opening on the side
allowed a bias flow of medical air to enter the box via a tube. Medical air was
introduced at a constant flow rate of approximately 4 Llmin in order to prevent the
accumulation of carbon dioxide in the box from exhaled air. The pneumotachometer
was placed in the opening on the roof of the flow chamber to record the child's
breathing pattern. The air flow through the two spacer devices is shown in figure 3.5.

Figure 3.4: Custom built flow chamber used to record breathing patterns in children
using either the Aerochamber Plus (pictured) or Funhaler.
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Figure 3.5: A: Air entrainment through the Aerochamber Plus spacer. B: Air
entrainment through the Funhaler spacer. Green arrows represent inhalation flow
and red arrows represent exhalation flow.

The flow chamber was kept air tight during the recording procedure and changes in
air pressure (air inhaled and exhaled through the spacer) were measured through the
membrane in the pneumotachometer. The pneumotachometer was connected to a
desk top computer which held the controlling software (Research Pneumotach
System, KORR Medical Technologies; Windows Software Version 3.07b), designed
to record breathing traces. Before each recording the pneumotachometer was
calibrated with a lL syringe (Koko, Pulmonary Data Service Instrumentation) and
the temperature and humidity in the clinic room was recorded. Each patient was
administered one actuation of a placebo pMDI via an actuation port on the flow
chamber at the start of inhalation and was asked to breathe for ten tidal breaths
through the spacer whilst their breathing pattern was recoded. Each trace was
digitally recorded at a flow range of 0-1 OOL/min at 50Hz via a computer and was
stored in a RSS (Really Simple Syndication) file format.
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All breathing traces were recorded using the spacer type the study subject was
randomised to. A clean detergent coated spacer (Anionic Detergent: Liquid Pyroneg,
Diversey, Australia) was used for each new recording. To keep the procedure as
natural as possible for the child, the flow chamber was designed to ensure minimal
difference in the child's normal drug administration experience. The breathing
pattern from each subject was later simulated in vitro using a Flow-Volume
Simulator (FVS) (see section 3.3.3.2 pg. 39).

3.3.2 Domiciliary Filter Study
At the end of the clinic session parents were provided with all the materials needed to
perform the domiciliary filter study (instruction sheet, 14 inspiratory filters, a new
salbutamol pMDI, filter labels and a storage box).

The domiciliary study was completed by the parent and child in their home, without
supervision from the researcher (JM). The filter-inhalation set-up and technique
required to perform the study was demonstrated to the parentis at the clinic visit by
the researcher and a take-home instruction sheet with diagrams was also provided.
Two filter set-up systems were used in this study, depending on which spacer type
the child was randomised to (Figure 3.2 & 3.3 pg. 32).

The filter set-up and administration procedure was identical to the pre- and posttraining filter studies performed in the clinic. The aerosolised drug was collected on
an inspiratory filter that was placed between the child's mouth and their spacer - the
child did not inhale any drug into their body. When the salbutamol pMDI
(lOOJ.!glactuation, Ventolin®) was actuated the quantity of drug which would
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normally be inhaled is deposited on the filter; this equates to the 'total body dose' of
drug which would have been inhaled by the child. The domiciliary study was
performed using the filters provided and the study medication for a period of one
week, after every normal routine administration of anti-inflammatory medication
(normally taken twice daily- morning and evening). Parents were asked to administer
five single actuations of salbutamol (shaking the pMDI before each actuation), while
the child took five tidal breaths from the spacer in synchronization with each
actuation. Before each administration, parents attached a new filter to the spacer, thus
14 samples were collected (two samples per day) for each child. After each filter was
completed parents were asked to wrap the filter in aluminium foil and store it in the
box provided until all filters were completed and collected from their home by the
researcher. Each filter was identified by an adhesive label affixed by the parent,
detailing filter number and time of day (am/pm).

This section of the study assessed daily variability of drug delivery in a more natural
setting. The home filters provide a more realistic representation of the total drug
administered as the delivery process takes place in the child's natural environment.
The child's regular medication regimen was not interfered with during the study as
the filter process took place after every prescribed administration and no additional
medication was inhaled.
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3.3.3 In Vitro Procedures
3.3.3.1 Waveform Conversion
Each original recorded breathing trace stored in a RSS file format was converted to a
FVW file format for compatibility with the FVS. Breathing traces were converted
using a waveform conversion program (RSS Waveform Editor, Hans Rudolph). The
program was able to subtract the bias flow (in Lisee) from the waveform which was
introduced during the recording. The same program was used to digitally cut the first
five consecutive breaths from each ten-breath breathing trace. The first five breaths
were used to keep all in vivo and in vitro procedures consistent (Figure 3.6).
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Figure 3.6: A representative five-breath breathing trace. Negative flow represents
inhalation and positive flow represents exhalation.
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3.3.3.2 Breathing Simulation

All recorded breathing traces from each child were simulated through a FlowVolume Simulator (FVS) (Series 1120 Hans Rudolph, Kansas, USA). A FVS is a
computer-controlled device consisting of a cylindrical piston which displaces air
according to the recorded breathing parameters of each breathing trace. An
inspiratory filter was placed between the breathing simulator and the spacer to
capture the delivered drug (Figure 3.7). The quantity of drug on the filter represented
the 'total body dose' of particles inhaled by the child. As with the clinic and
domiciliary filter studies, a total of five separate actuations of pMDI salbutamol
(100!-lg/actuation, Ventolin®)were delivered into the spacer. After each actuation the
five-breath trace was simulated to 'inhale' the drug (salbutamol was actuated
simultaneously with the start of inhalation). The salbutamol pMDI was shaken
thoroughly before each actuation. For each breathing trace the procedure was
repeated to obtain duplicate measurements. All inspiratory filters, spacers and
actuators were assayed as detailed in section 3.4 .1.
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Figure 3.7: A: Flow-volume simulator used to replicate breathing patterns recorded in children. B: Spacer, Filter, pMDI attached to
the FVS; the filter between the breathing simulator captures the delivered drug.
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Differences in the ambient conditions between the time of recording and the time of
simulation can alter the flow volumes, therefore before each· simulation the
temperature and humidity of the room was entered into the FVS program which
automatically corrected for any differences. Furthermore, prior to use, all spacers
were detergent coated in a 1:125 dilution of ionic detergent (Liquid Pyroneg,
Diversey, Australia) for 30 minutes and left to drip dry for 24 hours to diminish
electrostatic charge. The weight of the canister was measured before and after every
trial. The canister was disposed of at a weight of approximately 15g as doses become
more unpredictable after this weight.

3.3.3.3 Validation of the Flow-Volume Simulator

The use of a breathing simulator is based on the assumption that it will accurately
simulate a real-life human breathing trace and show a correlation between in vivo and
in vitro drug delivery. Therefore, an important part of this project was to validate

whether the FVS was able to replicate an in vivo measurement of drug dose. Eighteen
breathing traces from healthy adult subjects (40% male) aged 21-32 years (mean age
25) were recorded using a transparent flow chamber (the same flow chamber was
used to record the study subjects breathing patterns at the clinic visits) whilst in vivo
drug filter samples were taken. The airtight flow chamber contained a small volume
spacer (AC+) for measurement of in vivo drug delivery and a pneumotachometer to
record the subject's inspiratory parameters. Five individual actuations of pMDI
salbutamol were delivered into the spacer. Before each actuation the pMDI was
shaken vigorously and the subject's breathing trace was recorded (i.e. a total of five
breathing traces were recorded per subject). Salbutamol was captured on an
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inspiratory filter placed between the spacer and the subject's mouth (one filter was
used per subject).

In order for the FVS to recognise the breathing traces, each original recording was
converted from an RSS file to a FVW file format where the bias flow was subtracted
from the waveform. The breathing traces were then transferred to the FVS (FVS
represents the subject in vitro). An inspiratory filter was placed between the FVS and
the AC+ spacer to capture the drug. As with the breathing recording procedure a total
of five actuations of pMDI salbutamol were administered into the spacer device
individually. With each actuation the pMDI was shaken and the five separate
breathing traces for each subject were simulated in order of recording. One filter was
used per subject (i.e. for all five actuations and five breaths). All inspiratory filters
were analysed as detailed in section 3.4.1. There was a significant correlation
between in vivo and in vitro drug measurements (Figure 3.8).
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Figure3.8: A regression line showing the mean and ± 1.96 SD ofFVS drug dose (in
vitro) vs. in vivo drug dose. There was a significant correlation (r2= 0.85, p<O.OOl)
between the two measurements of drug delivery.

3. 3.3.4 Measurement of Breathing Parameters

The breathing parameters were measured for each recorded waveform. The original
(RSS file format) breathing trace was converted to a SIG file format using the
software that was initially used to record the breathing trace. The data from each
original waveform was then displayed and the bias flow (Lim) was removed. Each
breath from each waveform was analysed separately using a custom made software
program (Breathing Simulation Calculation- BSC; Programmer: Brad Zhang,
Princess Margaret Hospital) on the following breathing parameters: tidal volume,
inhalation volume, inhalation time, exhalation volume, exhalation time, peak
inhalation flow, time to peak inhale, peak exhalation flow and time to peak exhale.
The influence of these breathing parameters, age, height and weight were assessed on
drug delivery.
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3.4 Drug Analysis
3.4.1 Drug Recovery
Aerosolised salbutamol was recovered from inspiratory filters , actuators and spacers
using HPLC grade methanol. NaOH (0.1M) was added to all samples to increase the
absorbance sensitivity, and salbutamol was quantified using an ultraviolet (UV)
spectrophotometric method. To wash the filters, each filter was placed over the neck
of a Buchner flask, which was connected to a vacuum. Methanol was drawn through
the filter membrane, and collected in the flask. The solution was transferred into a 50
ml volumetric flask containing 5 ml ofNaOH, and methanol added to achieve a final
volume of 50 ml. Actuators used during the breathing simulation procedure were
washed with methanol into 25 ml volumetric flaks, each containing 2.5 ml ofNaOH.
Methanol was added to achieve a final volume of 25 ml. Spacers were washed twice;
methanol from each wash was transfened to two separate 50 ml volumetric flasks
with 5 ml NaOH, and methanol added to make a final volume of 50 ml.

The salbutamol content of all samples was determined using a UV spectrophotometer
(UV -1601, Shimadzu Scientific, Japan) at an optical wavelength of 246 nm, which
has been established from a calibrated analysis. All absorbance measures were
performed in duplicate and the mean for each was calculated. A five-point standard
curve was prepared each day using chemical reference salbutamol, with
concentration doses of 0.2, 0.5, 1.0, 1.5 and 2.0 1-tg/ml. Each standard contained a
10% (v/v) 0.1 M NaOH. Standard curves were linear within the concentration range
of 0.2 to 2.0 1-lg/ml. Methanol containing 10% (v/v) 0.1 M NaOH was used as a blank.
The amount of salbutamol in each sample was calculated (using the mean absorbance
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measure) from the standard curve that was prepared at the time the sample was
measured. The standard deviation and %CV for each sample was also calculated.

3.4.2 Validation ofMethod of Drug Recovery from Inspiratory Filters
The method of recovery and assay of salbutamol from inspiratory filters was
validated by placing a known amount of salbutamol on the filter membrane, then
extracting and analysing the amount of drug retrieved from the filter. Three different
doses of salbutamol were used: low (12.5 1-1-g), medium (50 1-1-g) and high (1250 1-1-g),
and each dose was tested in triplicate. Filters were assayed as detailed in section
3.4.1. The mean (range) absolute dose and proportion of drug recovered is shown in
Table 3.1.

Table 3.1: Validation filter results performed with salbutamol. The mean drug
recovered from the three repeats; expressed in absolute values and as a percentage
(%)(range). The standard deviation and percent coefficient of variance (%CV) also
shown for each dose.

Dose (IJ9)

Mean Dose
Recovered (IJg)

Mean% Recovery

STDEV

%CV

25.0 1-19

24.86

99.43 (98 .3-100.6)

1.18

1.18

50.0 IJQ

49.75

99.49 (99 .1- 100.3)

0.68

0.68

250 1-19

243.07

98.23 (96 .8-97.4)

0.34

0.35

3.4.3 Actuator Validation
Inconsistent dosing can be caused by differences in actuator moulds. Moulding can
vary from batch to batch; therefore it is important to test different actuator batches
for variable dosing. An Andersen Cascade Impactor (ACI; Andersen Instruments,
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USA), consisting of eight stages, a jet stage and a throat model (Figme 3.9), was
used to test six randomly selected actuators. Each stage of the ACI represents a
different particle size fraction with cut-off diameters of 9.0, 5.8, 4.7, 3.3, 2.1, 1.1 ,
0.7, 0.4 and 0 f.!m. The patiicle size distribution was calculated by evaluation of drug
impaction on each stage of the ACI. The fine particle fraction (FPF) corresponds to
the amount of drug available in particles <4 .7 f.!m in diameter, and are most likely to
deposit in the lung. The mass median aerodynamic diameter (MMAD) of an aerosol
examines the aerodynamic behaviour of the patiicles. The MMAD represents the
diameter of the aerosol particles at a cumulative distribution of 50%.

Each actuator was adapted to the throat of the ACI; ten actuations of salbutamol
pMDI were dispensed into the ACI in total (the pMDI canister was shaken for ten
seconds between each actuation), while a constant flow of 28.3 Llminute was drawn
through the ACI via a pump. The flow was calibrated using a digital flow meter
(Vitalograph; Model DFM2, Copley Scientific, UK) . All components of the ACI and
actuator were washed separately with methanol in 25 ml volumetric flasks; the drug
content was assayed using a UV spectrophotometer as detailed in section 3.4.1. The
drug output from each actuator was calculated by analysis of drug particle impaction
on each stage, the throat and actuator. There was minimal difference in drug output
between the individual actuators. These results are summarised in table 3.2 and
figure 3.1 0.
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Figure 3.9: An Andersen Cascade Impactor; consists of a throat, jet-stage,
eight-stages and a pump port. Broken arrows represent the flow direction at
28.3 Llmin.

Table 3.2: The total recovery, total exiting actuator, particles exiting actuator with
<4. 7 ~-tm shown in absolute values (~-tg) and percent of total recovery shown for each
actuator. Mass median aerodynamic diameter (MMDA) also shown for each
actuator. There were small discrepancies between the individual actuators.

Total
recovery
Actuator (J,Jg)
1
93.2
91 .6
2
3
92.7
92.7
4·
5
91 .3
6
92 .7

Total
exiting
actuator
(J,Ig)
78.2
78.6
82.9
81.3
78.5
79.3

Exiting
actuator
<4.7J,Jm
(J,Jg)
23.1
21.7
19.4
24.0
23.4
25.6

Exiting
T9tal
exiting
actuator
actuator <4.7J,Jm

(%)

(%)

83.9
85.8
89.5
87.7
85.9
85.6

24.8
23.7
20.9
25.9
25.7
27.6

MMAD
(J,Jm)
3.3
3.2
2.9
2.9
2.8
3.0
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Figure 3.10: The cumulative distribution (%) and particle diameter (!lm) for each
actuator tested. There were minimal differences between the six actuators tested.

3.5 Data Analysis
All statistical analyses were completed using SPSS software program (Version 12).
A statistician was also consulted to confirm that all analyses were conducted
appropriately. All filter doses were expressed as the amount (!lg) of drug deposited
on the filter per 100 Jlg actuation. Nose breathers were excluded from all analyses
and were assessed as a separate group. The effect of immediate training was assessed
by a two-way analysis of variance (ANOV A). Spacer type (AC+ I FH) was analysed
as a between subject factor, and the clinic training filters (pre and post) as within
subject factors. In addition, a one-way ANOVA was also performed to assess the
effect of repeated training on drug delivery by comparison of post-training filter
doses with the number of training sessions.
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The mean and standard deviation (SD) was calculated for each of the 14 domiciliary
filters collected from each child. The effect of any significant differences in drug
delivery in the domiciliary setting was assessed using a three-way ANOV A,
comparing spacer type (AC+ I FH) with day (1-7 days) and time of day (am/pm). A
two-way ANOV A was also used to evaluate if there were any significant differences
in drug delivery between the domiciliary setting and clinic setting. Spacer type was
used as a between subject factor and the average of the 14 domiciliary filters were
compared with the clinic post-training filter as within subject factors. A generalised
estimating equation with robust standard errors (weighted analysis) was also
performed to validate whether the difference in filter samples between the clinic and
home setting influenced the results . Fmihermore, an independent t-test was used to
compare the age distribution between the two spacer groups in order to validate if
age was a confounding factor for any of the between subject comparisons.

Coefficient of variance was used to assess intra- and inter- technique variability for
the FVS analysis. Regression analyses were performed to examine the effects of age,
height, weight and ce1iain breathing parameter (tidal volume, inhalation volume,
inhalation time, exhalation volume, exhalation time, peak inhalation flow, time to
peak inhale, peak exhalation flow and time to peak exhale) on drug delivery .
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CHAPTER4

RESULTS
This project was divided into three major categories evaluating the effects of in vivo
device technique training, in vivo drug delivery in the domiciliary setting and the
influence of age, height, weight and different breathing parameters on in vitro drug
delivery.

4.1 Study Population
The demographics of the study population for this project are summarised in table
4.1. A total of 47 children, 24 of whom were allocated to the FH arm and 23 to the
AC+ arm, attended a clinic session and underwent drug delivery assessment and
training. Of the 4 7 children recruited, four were analysed separately as these children
were identified as nose breathers (Table 4.1; nose breathers), and an additional two
withdrew from the domiciliary study after the clinic session was completed. Reasons
for withdrawal were non-compliance (n=1; FH) and the child's daily antiinflammatory medication being discontinued (n=1; AC+). All study participants were
similarly distributed for age and gender between the AC+ group and the FH group
(Table 4.1).
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Table 4.1: The study population; the mean age (range), gender (percent male) and
the spacer used (percent male) of children who attended the clinic session,
participated in the domiciliary study and were identified as nose breathers. There
were no significant differences in age and gender between the AC+ group and the FH
group.
AC+ Spacer

FH Spacer

p-value

Clinic Session (n=43)

Age (Months)
Gender

65.76 (42-90)
33% Male

60.50 (36-90)
33% Male

p>0.05
p>0.05

Domiciliary Study (n=41)

Age (Months)
Gender

66.95 (46-90)
33% Male

61.33 (36-90)
33% Male

p>0.05
p>0.05

Nose Breathers (n=4)

Age (Months)
Gender

45 (30-60)
25% Male

57.5 (55-60)
25% Male

p>0.05
p>0.05

4.2 Clinic-Based Technique Training
The effect of clinic-based training in pMDI administration and inhalation technique
was assessed on drug delivery in this section of the study.

In an overall analysis, the pre-training filter had a higher mean drug dose compared
to the post-training filter, however the magnitude of difference did not reach
statistical significance (p=0.078). There were no significant differences in technique
scores between the pre- and post- training assessments. Also, the type of spacer used
(AC+ or FH) had no significant effect on the filter doses (p=0.213). Furthermore, no
significant differences were found between the pre- and post- filters within the same
spacer group (AC+ p=0.483, FH p=O.l 05) (Figure 4.1 ). Finally, repeated training did
not result in a significant difference in drug delivery (p=0.151). However, there was
a significant difference in pMDI administration and inhalation technique scores at the
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baseline visit compared to visits 2 and 3 (p<O.OOl), but not compared to visit 1
(p>0.05) (Table 4.2).
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Figure 4.1: Drug dose (±SD) on the pre and post-training filters within the AC+ and
FH spacer groups. The decrease in dose between the pre and post filter was greater in
the FH group, but this decrease was not significant.

Table 4.2: Baseline and post-training clinic scores (% of skills performed correctly).
There was no significant difference in training scores between baseline and visit one.
There was a significant difference between baseline scores and visits three and four.

Number of Clinic
Visits

Baseline
Score(%)

Post-Training
Score(%)

1 (n=15)
2 (n=13)
3 (n=15)

83.9
79.7
77.4

89.6
94.1
93.9

p-value
p>0.05
p<0.001
p<0.001
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4.2.1 Nasal Inhalation
A total of four children, with a mean age 51 months (rarige 30-60 months) were
recognised as nose breathers from both spacer groups (AC+: n=2, FH: n=2). These
children were excluded from the overall analyses and were studied as a separate
group. The mean of the pre- and post- clinic filter doses for nose breathers and a
group of age-matched mouth breathers (n=4) is shown in figure 4.2 (the small
numbers didn't allow demonstration of statistical significance). Despite the distinct
discrepancy in drug delivery, technique evaluation scores (percent of correct skills
demonstrated) were similar for both mouth breathers and nose breathers (95%, 86%
respectively). The effect of nose breathing is further discussed in section 4.5.1.
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Figure 4.2: Clinic pre- and post-training filter doses (±SD). Comparison of drug
delivery between patients who performed mouth inhalation (n=4) and nose inhalation
(n=4).
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4.3 Drug Delivery in a Domiciliary Setting

Daily domiciliary inspiratory filters were collected over a period of seven days to
evaluate the difference in drug delivery in a more natural, non-clinical setting.

There was no significant difference in drug delivery between the individual days
(p=0.331) or the time of day (morning/evening) the medication was administered
(p=0.326). There was also no significant effect depending on the type of spacer used
and the day it was used (p=0.267), or the type of spacer used and time of day it was
used (p=O .131). An overall significant difference was found between morning and
evening doses, with evening administration exhibiting significantly higher drug
delivery (p=O.OOl ). Within the FH group evening doses were also significantly
higher (p=O.Ol5), however, no significant difference was found between morning
and evening doses in the AC+ group (p=0.381) (Figure 4.3). Furthermore, a
significant difference in drug delivery was found between the AC+ group and the FH
group (p=0.032), with the children using the AC+ receiving a higher mean dose
(Table 4.3). However, the AC+ group showed greater day-to-day variability, and had
a consistently higher standard deviation for both morning and evening doses
compared to the FH group (Figure 4.4).
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Figure 4.3: Morning and evening doses (±SD) for the seven days and the mean of both morning and evening doses. A: AC+ spacer group
(n=20); no significant difference between morning and evening doses. B: FH spacer group (n=21); evening doses were significantly higher.
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Table 4.3: The average of the morning and evening doses (Jlg) for each of the seven
days for the AC+ and FH spacer groups. The AC+ group had a significantly higher
mean dose than the FH.

Day 1
Day2
Day3
Day4
Day5
Day 6
Day7
Mean (±SD)

AC+

FH

38.02

27.97

38.08

27.33

38.03

28.81

40.02

27.79

35.22

27.70

32.87

28.31

33.39

28.03

36.52 (2.71)

27.99 (0.47)
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Figure 4.4: Morning and evening doses (±SD) for the AC+ and FH spacer. Day-today variability was greater in the AC+ group and the standard deviation for each day
was consistently higher.
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4.4 Drug Delivery in a Domiciliary and Clinical Setting
Overall, there was no significant difference in drug delivery between the domiciliary
setting and the clinic setting (p=0.75) (Figure 4.5). The mean drug dose between the
two spacer groups in the clinic setting was not significantly different (AC+; 32.11

~-tg

±14.27, FH; 31.01 1-tg ±14.27) (p=0.735). On the other hand, when drug delivery was
assessed in the domiciliary setting, the AC+ delivered significantly more drug
(Figure 4.6). Identical results were obtained using the generalised estimating
equation approach (weighted analysis).
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Figure 4.5: Average drug dose (±SD) in the domiciliary and clinic setting. There
was no significant difference in drug dose between the domiciliary setting and the
clinic setting.
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Figure 4.6: Average morning and evening doses (±SD) in the domiciliary setting and
the post-training filters in the clinical setting. There was a significant difference in
drug delivery between spacer groups in the domiciliary setting. However, there was
no significant difference in the clinic setting.

4.5 Flow-Volume Simulator Filter Dose Analysis

This section examines in vitro the effects of age, height, weight and breathing
parameters (tidal volume, inhalation volume, inhalation time, exhalation volume,
exhalation time, peak inhalation flow, time to peak inhalation, peak exhalation flow
and time to peak exhalation) on drug delivery.

There were no significant differences in the breathing parameters between the AC+
spacer group and the FH spacer group (Table 4.4). Overall, correlations between
drug delivery and the analysed parameters were weak (r2 = 0.005 - 0.272). When the
two spacer groups were examined separately, significant correlations were found
within the AC+ group but not the FH group. In the AC+ group drug delivery was
significantly positively associated with peak inhalation flow (p=O.OOI), age
(p=0.002), tidal volume (p=0.003), inhalation volume (p=0.003), exhalation volume
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(p=0.004), height (p=0.005), weight (p=0.014) and peak exhalation flow (p=0.027)
(Table 4.5). Peak inhalation flow and age were the most significantly associated with
drug delivery; these two parameters are compared between the two spacer groups in
figures 4.7 and 4.8.

Table 4.4: The mean (standard deviation) of the different breathing parameters for
the AC+ group and the FH group. There were no significant differences between the
two groups.

AC+

FH

Breathing Parameters
Tidal volume (mls)

Mean (±SD)

Mean (±SD)

98.81 (65.76)

103.9 (36.36)

Inhalation Volume (mls)
Inhalation Time (sec)
Peak Inhalation Flow (mls/sec)
Time to Peak Inhalation
Exhalation Volume (mls)
Exhalation Time (sec)
Peak Exhalation Flow (mls/sec)
Exhalation Volume (mls)
Time to Peak Exhalation (mls/sec)

47.88 (31.78)
0.83 (0.25)

44.71 (17.27)
0.93 (0.31)

5646 (3329)

4537(1896)

6.41 (8.21)
50.73 (34.59)

4.47 (1 .34)
58.73 (21.69)

1.23
4001
50.73
5.54

1.02
5052
58.96
5.18

(0.42)
(2727)
(34.59)
(1 .57)

(0.36)
(1771)
(22.20)
(1.59)

p-value
p>0.05
p>0.05
p>0.05
p>0.05
p>0.05
p>0.05
p>0.05
p>0.05
p>0.05
p>0.05

Table 4.5: Parameters significantly associated with drug delivery in the AC+ group.
Each parameter is shown in order of the strength of correlation (r2) and significance
(p-value).

Parameters
Peak Inhalation Flow
Age
Tidal volume
Inhalation Volume
Exhalation Volume
Height
Weight
Peak Exhalation Flow

Correlation
(r2)
0.451
0.403
0.387

p-value
0.001
0.002
0.003

0.385
0.365

0.003

0.349

0.005
0.014

0.278
0.231

0.004

0.027
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Figure 4.7: The effect of peak inhalation flow on drug dose. A: There was a
significant correlation between PIF and drug dose in the AC+ group (r2= 0.451 ,
p=O.OOl). B: There was no significant correlation between PIF and drug dose in the
FH group (r2= 0.008, p=0.691).
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Figure 4.8: The correlation between age and drug dose. A: There was a significant
correlation between age and drug dose in the AC+ group (r2 = 0.403, p=0.002). B:
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4.5.1 Nasal Inhalation
Children who inhaled through their nose were further examined by analysis of
individual breathing traces. The difference in breathing trace patterns between a
typical mouth breather and a nose breather is shown in figure 4.9. As expected, the
drug dose delivered to patients who perform nasal inhalations was extremely low.
The difference in mean drug delivery between the nose breathers and a group of agematched mouth breathers (n=4) is shown in figure 4.10. The small numbers didn't
allow demonstration of statistical.significance. This is only preliminary data; further
analysis with a larger cohort is needed in order to attain a better understanding of this
sub-group of patients.
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Figure 4.9: Representative breathing traces. Negative flow represents inhalation and
positive flow represents exhalation. A: Breathing trace of a mouth breather. B:
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CHAPTERS

DISCUSSION

Ineffective drug delivery is a common problem in the paediatric age group, resulting
in increased symptoms and a decreased quality of life for both children and parents
[5-7]. In order to improve future asthma care, it is important to isolate the sources of
variability in drug delivery and implement new tactics in an effort to improve drug
delivery. The aim of this study was to examine factors that affect delivery of inhaled
aerosol medications and investigate whether certain strategies improve drug delivery
in pre-school age children.

5.1 Clinic-Based Technique Training
The pMDI-spacer combination is often used incorrectly by children and parents,
causing sub-optimal drug delivery to the airways, and thus increasing the risk of
adverse systemic side-effects and dangerous asthma exacerbations [5, 6, 129, 130].
The effect of clinic-based technique training on drug delivery was investigated in this
section of the project. The population for the present study was recruited from an
existing study with a larger cohort, where the children attended regular clinic
sesswns for 12 months and received device technique training. The number of
training sessions received from the larger study was dependent on the number of
clinic visits attended, thus the children in the present sub-study had all obtained
various amounts of training prior to their clinic session.
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In the clinic session two drug delivery measurements were conducted with each
child; a pre- and a post-training filter. The pre-filter sample was taken before the
parent was trained on pMDI-spacer administration technique and the child on
inhalation technique at that visit. Once the training session had occurred and errors
were corrected a post-training filter sample was taken.

In order to achieve the full benefits of therapy, effective inhaler technique is essential
[15, 26, 124]. Former studies have not previously assessed the effects of clinic-based
technique training by integrating a qualitative analysis (check-list score) with a
measure of drug delivery. The present study evaluated the parent's pMDI technique
and the child's inhalation technique, before and after training, according to a
criterion check-list of essential procedures, whilst collecting measurements of drug
delivery. The effect of immediate training was measured by comparison of the preand post-training filters. Overall, there was no significant difference in drug delivery,
or technique scores, between pre-training and post-training. Therefore, these results
show that clinic-based training had no immediate positive effect on technique or drug
delivery. From the qualitative analysis, the most common errors performed were
parents not shaking the pMDI canister before every actuation and children taking
their mouth away from the spacer after actuation; these findings are in accordance
with other studies [103, 129, 132]. The greatest improvement in technique was
parents shaking the pMDI canister before every actuation, and as this technique was
dependent on the parent it was more easily corrected, as opposed to keeping a tight
seal on the mouth piece of the spacer, which was dependent on the child.
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Our laboratory has found that shaking the pMDI before every actuation is essential
with corticosteroid suspension delivery (i.e. fluticasone ), as the drug particles
separate rapidly from the propellant, resulting in minimal release of the effective
compound (unpublished data). However, previous studies have shown that the drug
particles do not separate as rapidly with salbutamol. This was originally shown using
CFC salbutamol [144], and has been confirmed in our laboratory using HFA
salbutamol (unpublished data). Therefore, once the pMDI canister has been
rigorously shaken prior to the initial actuation, shaking between subsequent
actuations is not essential. As salbutamol was used as a marker of drug delivery in
this study, shaking may not have , caused a significant difference in drug dose,
however, there may have been a great difference with inhaled corticosteroids.
Fluticasone was deliberately not used in the present study due to the masking effect
(i.e. not shaking the pMDI within seconds of actuation may result in huge changes in
drug delivery), as a range of device technique issues were being examined, not just
one. However, since the greatest improvement in technique was shaking of the pMDI
canister, it would be worth assessing if this specific change in technique results in a
significant improvement in delivery of corticosteroid suspension formulations.

The effect of repeated training was also assessed by comparison of post-training
filter doses (i.e. drug dose after training) with the total number of training sessions
attended. At the end of the clinic visit all children had acquired two, three or four
training sessions in total; this includes any previous training received from the larger
study. The results obtained show that repeated pMDI-spacer technique training in
pre-school children and their parents had no significant effect on drug delivery.
Previous studies have found that regular training improves device technique skills in
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both children and parents [17-21]. Based on a standardised check-list of essential
technique steps, Kamps et al. [19] found that 93% of children (mean age 5 years)
who had received at least two training sessions could perform all vital steps
correctly, compared to 58% who had not received repeated training. Foland and
colleagues [20] also assessed the effects of training in older patients (mean age 9.2
years) and found that after repeated training children were able to perform at least
seven out of eight essential steps correctly without prompting. However, these
studies have some limitations, namely, the form of assessment was only qualitative;
thus the patients technique, before and after training, was assessed by the
investigator's perception of competence according to a criterion check-list of
essential device administration procedures and skills. Additionally, these studies
have not shown whether perceived improvement in technique correlates with
improvement in drug delivery and clinical efficacy, which are the most relevant
outcomes. Wilson et al. [145] incorporated an observational analysis (check-list
score) with patient reports of asthma symptoms, and found that technique scores
increased over a one year follow-up and self-reported asthma symptoms decreased.
Nevertheless, it is well established that objective assessment is the most accurate, as
it does not rely on patient reports and observation [13].

The present study integrated both qualitative and quantitative methods of assessment.
Although it was anticipated that there would be a direct correlation between drug
delivery and technique evaluation the results from the present study show that
technique scores improved after three training sessions from baseline, but drug
delivery did not. These results, along with other findings, suggest that while an
observational analysis of technique may be adequate to correct gross errors which
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may sufficiently impact on the efficiency of inhaler technique, more objective
methods are needed to identify less obvious errors [146]. Pedersen et al. [129]
showed that children who had previously been assessed with objective methods, such
as lung function measurements, exhibited better technique, as errors were more
readily noticed and corrected, compared to children who did not receive this form of
training. This issue is of immense importance and has also been highlighted in the
present study. By assessing drug delivery, it was possible to identify children who
perform nasal inhalation. These children would not have been recognised by a
standard observational analysis alone, and consequently the error in technique could
not have been corrected. Patients who breathe through their nose inhale very little, if
any drug into their body; hence an error that has a huge impact on drug delivery
would have been unrecognised if an objective measure was not incorporated in the
present study.

This study assessed drug delivery, which is an intermediate measure between an
observational analysis and clinical efficacy. Lung function measurements provide a
more coherent evaluation of technique performance and clinical efficacy by showing
whether the drug is actually inhaled into the lungs, which is the primary aim of
training. Future studies should include objective measures based on clinical efficacy,
such as lung function tests, to conclusively determine the effects of inhaler technique
training and. ensure all essential skills are performed optimally.

Qu~litative

analyses of the clinic-based video-recordings were conducted to closely

observe the manner in which the children interacted with the spacer devices.
Children using the AC+ spacer appeared to be more focused on their inhalation
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technique and the administration procedure, compared to the children using the FH
spacer. Children with the FH spacer seemed to treat the spacer more like a toy, and
thus were more likely to misbehave and less likely to concentrate on their breathing.
Although these results are preliminary, it is plausible to suggest that perhaps children
associate the FH spacer with 'play time', and as a result may be more inclined to play
about during the administration procedure. However, the AC+ spacer may be seen as
more of a 'medical device', which could possibly encourage children to adopt a more
serious attitude during the administration procedure. The behaviour seen with the FH
spacer is directly opposite to what was intended with the use of the incentive device.

5.2 Drug Delivery in the Domiciliary Setting

It is not only essential to assess drug delivery in a clinical setting, but also outside the
clinic, in a more natural setting. The domiciliary setting provides a more realistic
representation of drug delivery, as the 'white coat' effect disappears and the child is
in a more comfortable environment. This section of the study assessed drug delivery,
with use of the AC+ and FH spacer devices, in daily life over a period of one week.
In order to keep the home environment as natural as possible a study supervisor was
not present during the domiciliary study.

The results obtained showed there was no difference in drug dose between individual
days, thus the children did not perform better or worse on certain days. However, the
AC+ spacer group exhibited significantly higher drug delivery consistently over the
seven days compared to the FH spacer group. In addition, there were no differences
between evening and morning doses in the AC+ group; however the FH group had
significantly higher evening doses compared to morning doses. These findings
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suggest that technique compliance and co-operation was greater with the AC+ spacer
compared to the FH spacer. Moreover, the consistency between morning and evening
doses in the AC+ group suggests that compliance to good technique was constant
with the AC+ spacer regardless of the time of day the spacer was used, but not with
the FH spacer. These results are in contradiction to Watt et al. [1] who found that
adherence and technique compliance increased in children and parents with the FH
spacer, compared to a standard spacer device, in the home setting over a two-week
period. However, this study assessed the long-term effects of the FH spacer (all
children had been using the FH for a period of three to nine months), using an
objective measure, namely on drug delivery. The earlier study was conducted over a
shorter period of time (two-weeks) using more subjective measures (parental report
via questionnaire). Therefore, even though improvement in adherence and technique
was previously seen, the results found here show that when children use the FH
spacer over a longer period of time there is no improvement in drug delivery. An
explanation for the two opposing findings could be that children are initially excited
by the incentive toys and the novel device, however with constant use over time, the
novelty begins to fade and children become bored. In addition, even though a study
supervisor was not present during the domiciliary study, based on the clinic video
evaluations, it is plausible to suggest that children who were using the FH spacer
were more likely 'play about' in the home, compared to children using the AC+
spacer. Hence, this preliminary data demonstrates that particularly with prolonged
use, 'toy' incentive devices may actually decrease co-operation and drug delivery to
children.
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5.3 Flow-Volume Simulator Drug Dose
Isolating factors that are important in drug delivery in young patients is an essential
step to improving health outcomes. This component of the project examined the
effects of age, height, weight and breathing parameters (tidal volume, inhalation
volume, inhalation time, exhalation volume, exhalation time, peak inhalation flow,
time to peak inhale, peak exhalation flow and time to peak exhale) on in vitro drug
delivery. Breathing traces were recorded from all children during their clinic session
and were subsequently simulated using a FVS.

The AC+ spacer showed a significant positive association between drug delivery and
age, height, weight, tidal volume, peak inhalation flow, inhalation volume,
exhalation volume and peak exhalation flow. However, no significant associations
were found between any of the parameters investigated with the FH spacer.

Age, height and weight are all indicators of lungs size [147, 148]; thus the positive
.association between drug delivery and the age, height and weight of a patient
suggests that the AC+ spacer provides a form of dose correction for lung size. This
means smaller children will inhale less drug compared to larger children when using
the AC+ spacer. The advantage of dose correction is that children receive a dose
relative to their lung/body size, and as a result fewer side-effects will be experienced.
This is especially important with inhaled corticosteroid treatment as there are many
potential adverse side-effects associated with over treatment [28, 95].

Drug delivery with the FH spacer was shown to be independent of the child's age.
Furthermore, the non-significant positive association between drug delivery and the
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breathing parameters indicates that dose delivery is also independent of the patients
breathing parameters. Therefore, the FH spacer would be ideal to use in emergency
situations where the child may not be able to perform optimal breathing, but would
still receive an adequate dose of medication independent of their age. An example of
this could be in situations of airway obstruction, where the child will not be capable
of performing effective breathing, but will need a large dose of a beta2 agonist
independent of their age.

5.3.1 Nasal Inhalation
It is difficult to identify patients who perform nasal inhalation by observation, more

objective measures are needed. As was the case in this study, children who inhaled
through their nose were identified by assessment of drug delivery and analysis of
individual breathing traces. There were a total of four children (AC+: n=2, FH: n=2)
who were recognized as nose breathers; mean age 51 months (range: 30-60 months).
These children were excluded from the overall analyses and were studied as a
separate group.

Drug delivery was compared between the identified nose breathers and a group of
age-matched mouth breathers, and as expected the dose inhaled by patients who
breathed nasally was extremely low. The results show that on average mouth
breathers can inhale up to 24
inhaled 4

~g.

~g

of drug, compared to nose breathers who only

The magnitude of this difference clearly illustrates that with each

administration patients who inhale through their nose can receive up to 20 1-tg less
drug than patients who breathe through their mouth. The use of a nose clip can be
incorporated with each administration in an attempt to encourage mouth breathing;
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however many children resist this and compliance becomes a problem, especially in
the home where children are even less likely to be co-operative. These findings are
preliminary and certainly warrant further investigation into this sub-group of
patients.

5.4 Comparison of the Two Spacer Devices (AC+ and FH)
No significant difference was found in drug delivery between the two spacers in the
clinic setting. However, when tested in the home, the AC+ spacer was shown to
provide a significantly higher drug dose compared to the FH spacer. Previous
literature has shown that there is' considerable variation in drug delivery from
different spacer devices in daily life [1 0, 16]. The domiciliary setting, as opposed to a
clinical setting, provides a more accurate representation of drug delivery and device
use in a daily life situation, as this is the primary setting where drug administration
occurs. Before prescribing an inhaler device, it is important for clinicians to consider
that a child's performance in the clinic setting is not always reflected in a daily life
situation. By examining the effects of the FH spacer in a clinical and domiciliary
setting, it was found that even though the FH would be ideal to use in emergency
situations, it would not be ideal for every day use. The children seemed to treat the
FH spacer as too much of a toy, which caused the 'play' issue, and in tum
compromised drug delivery. Hence, with long-term use the incentive effective of the
FH spacer appears to vanish.

Drug delivery with the AC+ spacer was shown to be dependent on the patient's
breathing parameters. As children are more likely to show variation in their breathing
technique, variability in drug delivery would also be more common with the AC+
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spacer. This was evident in the domiciliary study where more variability was seen
between doses with the AC+ spacer. However, despite this, the AC+ spacer still
delivered a significantly higher dose compared to the FH spacer. This suggests that
children exhibit better technique and were more co-operative with the AC+
compared to the FH spacer. Thus, this study has shown that even though the AC+
spacer may have some limitations, children perform better in the home with the AC+
spacer, compared to an incentive spacer such as the FH.

Due to time restrictions, this study was only able to provide preliminary data on
inhaler technique training and the use of an incentive spacer device compared to a
standard device in pre-school children. These issues will be more comprehensively
analysed in the larger longitudinal study. Furthermore, this study was a non-blinded
study, thus both investigators and subjects were aware of which spacer type was
being used, however as one of study objectives was to evaluate the way children
interact with the two different spacer devices, blinding was unsuitable.

5.5 Future Research
Both the present study and the longitudinal study examined drug delivery in terms of
the 'total body dose' of drug inhaled by the patients, not drug delivery to the lungs,
specifically; therefore future research will involve radio-labelling lung deposition
studies, in order to evaluate the deposition of drug particles in the respiratory tract.
Furthermore, increasing the sample size and furthering the development of new
patient inhaler training strategies, particularly aimed at nose breathers, is another
possible area for future research.

73

REFERENCES
1.

2.
3.

4.

5.
6.

7.

8.
9.

10.

11.
12.
13.

14.
15.

16.

17.

Watt, P.M., B. Clements, S.G. Devadason, and G.M. Chaney, Funhaler
spacer: improving adherence without compromising delivery. [Electronic
version}. Archives ofDisease in Childhood, 2003. 88(7): p. 579-581.
Devadason, S.G., Recent Advances in Aerosol Therapy for Children with
Asthma. Journal of Aerosol Medicine, 2006. 19(1): p. 61-66.
Gibson, N., A. Ferguson, T. Aitchison, and J. Paton, Compliance with inhaled
asthma medication in preschool children. Thorax, 1995. 50(12): p. 12741279.
National Asthma Council, Asthma Management Handbook. 2002: National
Asthma Council Australia.
Gillies, J., Overview of delivery system issues in pediatric asthma [Electronic
version}. Pediatric Pulmonology Supplement, 1997. 15: p. 55-8.
Giraud, V. and N. Roche, Misuse of corticosteroid metered-dose inhaler is
associated with decreased asthma stability. Eur Respir J, 2002. 19(2): p. 246251.
Celano, M., R.J. Geller, K.M. Phillips, and R. Ziman, Treatment adherence
among low-income children with asthma [Electronic version]. Journal of
Pediatric Psychology, 1998. 23(6): p. 345-9.
Hill, D.G., Running on empty: metered dose inhaler compliance, technique,
and delivery. Asthma Manage, 1996. 5: p. 74-76.
Janssens, H.M., J.C. De Jongste, and H.A. Tiddens, Aerosol Therapy and
Delivery Systems in Young Children: Science and practice, in Aerosol
Therapy in Young Children. 2001, Netherlands: Asthma Foundation. p. 1958.
Janssens, H., E. Heijnen, V. de Jong, W. Hop, W. Holland, and H. Tiddens,
Aerosol delivery from spacers in wheezy infants: a daily life study [Electronic
version}. Eur Respir J, 2000. 16(5): p. 850-856.
Smith, N.A., J.P. Seale, and J. Shaw, Medication compliance in children with
asthma. Australian Paediatric Journal, 1984. 20(1): p. 47-51.
Chapman, K.R., L. Walker, S. Cluley, and L. Fabbri, Improving patient
compliance with asthma therapy. Respiratory Medicine, 2000. 94(1): p. 2-9.
Bender, B., H. Milgrom, and C. Rand, Nonadherence in asthmatic patients: is
there a solution to the problem? Annals of Allergy, Asthma, & Immunology,
1997. 79(3): p. 177-85.
Matsui, D.M., Drug adherence in pediatrics: Clinical and Research issues.
New Frontiers in Pediatric Drug Therapy, 1997. 44: p. 1-14.
Cochrane, M.G., M.V. Bala, K.E. Downs, J. Mauskopf, and R.H. Ben-Joseph,
Inhaled corticosteroids for asthma therapy: patient compliance, devices, and
inhalation technique [Electronic version]. Chest, 2000. 117(2): p. 542-50.
Janssens, H.M., S.G. Devadason, W.C. Hop, P.N. LeSouef, J.C. De Jongste,
and H.A. Tiddens, Variability of aerosol delivery via spacer devices in young
asthmatic children in daily life [Electronic version]. European Respiratory
Journal, 1999. 13(4): p. 787-91.
Gracia-Antequera, M. and M. Morales Suarez-Varela, An intervention to
improve the inhalatory technique of children and adolescents with asthma
[Electronic version}. Allergologia et Immunopathologia, 1999. 27(5): p. 25560.
74

18.

19.

20.

21.

22.

23.
24.

25.

26.
27.
28.

29.
30.

31.
32.

33.

Kamps, A.W., P.L. Brand, and R.J. Roorda, Determinants of correct
inhalation technique in children attending a hospital-based asthma clinic
[Electronic version]. Acta Paediatrica, 2002. 91(2): p. 159-63.
Kamps, A.W., B. van Ewijk, R.J. Roorda, and P.L. Brand, Poor inhalation
technique, even after inhalation instructions, in children with asthma
[Electronic version]. Pediatric Pulmonology, 2000. 29(1): p. 39-42.
Foland, A.P., T. Stern, B.A. Ramacciotti, J.E. Martin, I. Gilbert, and R.C.
Cohn, Improvement of Metered-Dose Inhaler Administration Technique: The
Effect of Training Sessions at a Specialized Pediatric Asthma Compliance
and Technique Clinic. Current Therapeutic Research, 2002. 63(2): p. 142147.
Marguet, C., L. Couderc, P. LeRoux, E. Jeannot, V. Lefay, and E. Mallet,
Inhalation treatment: errors in application and difficulties in acceptance of
the devices are frequent in wheezy infants and young children. [Electronic
version]. Pediatric Allergy & Immunology, 2001. 12(4): p. 224-30.
O'Connell, E.J., Optimizing inhaled corticosteroid therapy in children with
chronic asthma. [Electronic version]. Pediatric Pulmonology, 2005. 39(1): p.
74-83.
Everard, M.L., Role of inhaler competence and contrivance in "difficult
asthma". Paediatric Respiratory Reviews, 2003. 4(2): p. 135-42.
Nikander, K., J. Denyer, N. Smith, and P. Wollmer, Breathing patterns and
aerosol delivery: impact of regular human patterns, and sine and square
waveforms on rate of delivery. Journal of Aerosol Medicine, 2001. 14(3): p.
327-33.
Janssens, H.M., A. Krijgsman, T.F. Verbraak, W.C. Hop, J.C. de Jongste, and
H.A. Tiddens, Determiningfactors of aerosol depositionfor four pMDIspacer combinations in an infant upper airway model. Journal of Aerosol
Medicine, 2004. 17(1): p. 51-61.
Bone, R.C., Goals of asthma management. A step-care approach [Electronic
version]. Chest, 1996. 109(4): p. 1056-65.
Global Initiative for Asthma, Pocket Guide for Asthma Management and
Prevention. 2005, GINA: Global Initiative for Asthma.
National Institutes ofHealth, Expert Panel Report 2: Guidelines for the
Diagnosis and Management ofAsthma. 1997, U.S Depmiment of Health and
Human Services: National Institutes of Health.
Haahtela, T., The importance of inflammation in early asthma. [Electronic
version]. Respiratory Medicine, 1995. 89(7): p. 461-462.
Laitinen, L.A., A. Laitinen, and T. Haahtela, Airway mucosal inflammation
even in patients with newly diagnosed asthma. American Review of
Respiratory Disease, 1993. 147(3): p. 697-704.
Goldsby, R., T. Kindt, B. Osborne, and J. Kuby, Immunology: Fifth Edition.
2003: Freeman and Company.
Elias, J.A., Z. Zhu, G. Chupp, and R.J. Homer, Airway remodeling in asthma.
[Electronic version]. Journal of Clinical Investigation, 1999. 104(8): p. 10016.
Chetta, A., A. Foresi, M. Del Donno, G. Bertorelli, A. Pesci, and D. Olivieri,
Airways remodeling is a distinctive feature of asthma and is related to
severity of disease. [Electronic version]. Chest, 1997. 111(4): p. 852-7.

75

34.

35.

36.

37.

38.

39.

40.
41.

42.
43.

44.

45.

46.

47.

48.
49.
50.

Jeffery, P.K., Remodeling in asthma and chronic obstructive lung disease.
[Electronic version]. American Journal of Respiratory & Critical Care
Medicine, 2001. 164(10 Pt 2): p. S28-38.
Tulic, M.K., Bergeron, C., Daigneault, P., Hamid, Q., Developmental
Features ofAirway Remodelling, in Childhood Asthma. 2006, New York:
Taylor & Francis. p. 71-97.
Martinez, F.D., Development of Wheezing Disorders and Asthma in
Preschool Children. [Electronic Version]. Pediatrics, 2002. 109(2): p. 362367.
Leung, D.Y., J.D. Spahn, and S.J. Szefler, Immunologic basis and
management of steroid-resistant asthma. Allergy Asthma Proc., 1999. 20(1):
p. 9-14.
Szefler, S. and D. Leung, Glucocorticoid-resistant asthma: pathogenesis and
clinical implications for management [Electronic version]. European
Respiratory Journal, 1997. 10(7): p. 1640-1647.
Stein, R., C. Holberg, W. Morgan, A. Wright, E. Lombardi, L. Taussig, and
F. Martinez, Peak flow variability, methacholine responsiveness and atopy as
markers for detecting different wheezing phenotypes in childhood. Thorax,
1997. 52(11): p. 946-952.
Sears, M.R., Consequences of long-term inflammation. The natural history of
asthma. Clinics in Chest Medicine, 2000. 21(2): p. 315-29.
Pedersen, S., Early Pharmacologic Intervention ofAsthma: How Early and
What Treatment?, in Childhood Asthma. 2006, New York: Taylor & Francis.
p. 213-251.
Redington, A.E., Fibrosis and airway remodelling. Clinical & Experimental
Allergy, 2000. 1: p. 42-5.
Alford, S.H., E. Zoratti, E.L. Peterson, M. Maliarik, D.R. Ownby, and C.C.
Johnson, Parental history of atopic disease: Disease pattern and risk of
pediatric atopy in offspring. Journal of Allergy and Clinical Immunology,
2004. 114(5): p. 1046-1050.
Aberg, N., J. Sundell, B. Eriksson, B. Hesselmar, and B. Aberg, Prevalence
of allergic diseases in schoolchildren in relation to family history, upper
respiratory infections, and residential characteristics. Allergy, 1996. 51(4):
p. 232-7.
Ronmark, E., B. Lundback, E. Jonsson, A.C. Jonsson, M. Lindstrom, and T.
Sandstrom, Incidence of asthrna in adults- report from the Obstructive Lung
Disease in Northern Sweden Study. Allergy, 1997. 52(11): p. 1071-8.
Koeppen-Schomerus, G., J. Stevenson, and R. Plomin, Genes and
environment in asthma: a study of 4 year old twins. [Electronic version].
Arch Dis Child, 2001. 85(5): p. 398-400.
Harris, J.R., Magnus, P., Samuelsen, S., Tambs. K., No Evidence for Effects
of Family Environment on Asthma . A Retrospective Study of Norwegian
Twins. Am. J. Respir. Crit. Care Med., 1997. 156(1): p. 43-49.
Kabesch, M., Mutius, E.V., Epidemiology and public health, in Childhood
Asthma and Other Wheezing Disorders. 2002, Great Britain: Arnold. p. 9-28.
Lundback, B., Epidemiology of rhinitis and asthma. [Electronic version].
Clinical & Experimental Allergy, 1998. 2: p. 3-10.
Noakes, P.S., J. Hale, R. Thomas, C. Lane, S.G. Devadason, and S.L.
Prescott, Maternal smoking is associated with impaired neonatal Toll-like

76

51.

52.

53.

54.

55.
56.

57.

58.

59.

60.

61.

62.

63.

64.

receptor (I'LR) mediated immune responses. European Respiratory J oumal,
. 2006. 26: p. 26.
Sears, M., M. Holdaway, E. Flannery, G. Herbison, and P. Silva, Parental
and neonatal risk factors for atopy, airway hyper- responsiveness, and
asthma. Arch Dis Child, 1996. 75(5): p. 392-398.
Hanrahan, J.P., LB. Tager, M.R. Segal, T.D. Tosteson, R.G. Castile, H. Van
Vunakis, S.T. Weiss, and F.E. Speizer, The effect of maternal smoking during
pregnancy on early infant lung function. American Review of Respiratory
Disease, 1992. 145(5): p. 1129-35.
Tager, LB., J.P. Hanrahan, T.D. Tosteson, R.G. Castile, R.W. Brown, S.T.
Weiss, and F.E. Speizer, Lung function, pre- and post-natal smoke exposure,
and wheezing in the first year of life. American Review of Respiratory
Disease, 1993. 147(4): p. 811-7.
Strachan, D.P. and D.G. Cook, Parental smoking and childhood asthma:
longitudinal and case-control studies. [Electronic version}. Thorax, 1998.
53(3): p. 204-212.
Flaherman, V., Rutherford, G.W., A meta-analysis of the effect of high weight
on asthma. Arch Dis Child, 2006. 91(3): p. 334-339.
Haby, M.M., J.K. Peat, G.B. Marks, A.J. Woolcock, and S.R. Leeder, Asthma
in preschool children: prevalence and risk factors [Electronic version}.
Thorax, 2001. 56: p. 589-595.
Farchi, S., F. Forastiere, N. Agabiti, G. Corbo, R. Pistelli, C. Fortes, V.
Dell'Orco, and C.A. Perucci, Dietary factors associated with wheezing and
allergic rhinitis in children. Eur Respir J, 2003. 22(5): p. 772-780.
Cook, D., I. Carey, P. Whincup, 0. Papacosta, S. Chirico, K. Bruckdorfer,
and M. Walker, Effect offresh fruit consumption on lung function and wheeze
in children. [Electronic version}. Thorax, 1997. 52(7): p. 628-633.
Peat, J., E. Tovey, B. Toelle, M. Haby, E. Gray, A. Mahmic, and A.
Woolcock, House dust mite allergens. A major risk factor for childhood
asthma in Australia. Am. J. Respir. Crit. Care Med., 1996. 153(1): p. 141146.
Wahn, U., S. Lau, R. Bergmann, M. Kulig, J. Forster, K. Bergmann, C.P.
Bauer, and I. Guggenmoos-Holzmann, Indoor allergen exposure is a risk
factor for sensitization during the first three years of life. J oumal of Allergy
& Clinical Immunology, 1997. 99(6 Pt 1): p. 763-9.
Kuehr, J., T. Frischer, R. Meinert, R. Barth, J. Forster, S. Schraub, R.
Urbanek, and W. Karmaus, Mite allergen exposure is a risk for the incidence
of specific sensitization. Journal of Allergy and Clinical Immunology, 1994.
94(1): p. 44-52.
Lau, S., S. Illi, C. Sommerfeld, B. Niggemann, R. Bergmann, E. von Mutius,
and U. Wahn, Early exposure to house-dust mite and cat allergens and
development of childhood asthma: a cohort study. The Lancet, 2000.
356(9239): p. 1392-1397.
Gereda, J., D. Leung, A. Thatayatikom, J. Streib, M. Price, M. Klinnert, and
A. Liu, Relation between house-dust endotoxin exposure, type I T-cell
development, and allergen sensitisation in infants at high risk of asthma
[Electronic version}. The Lancet, 2000. 355(9216): p. 1680-1683.
Riedler, J., C. Braun-Fahrlander, W. Eder, M. Schreuer, M. Waser, S.
Maisch, D. Carr, R. Schier!, D. Nowak, E. von Mutius, and A.S. Team,
Exposwe to farming in early life and development of asthma and allergy: a

77

65.
66.
67.

68.

69.

70.

71.

72.
73.

74.
75.

76.

77.

78.
79.

80.
81.

cross-sectional survey [Electronic version]. Lancet, 2001. 358(9288): p.
1129-33.
Douwes, J. and N. Pearce, Asthma and the westernization 'package'
[Electronic version]. Int. J. Epidemiol., 2002. 31(6): p. 1098-1102.
Bousquet, J., A physician's view of health economics in asthma. European
Respiratory Journal, 1995. 5(30): p. 275-8.
Pearce, N. and J. Douwes, The global epidemiology of asthma in children.
International Journal of Tuberculosis & Lung Disease, 2006. 10(2): p. 12532.
Beasley, R., P. Ellwood, and I. Asher, International patterns of the
prevalence ofpediatric asthma the ISAAC program. Pediatric Clinics of
North America, 2003. 50(3): p. 539-53.
Poulos, L.M., B.G. Toelle, and G.B. Marks, The Burden ofAsthma in
Children: An Australian Perspective. [Electronic version]. Paediatric
Respiratory Reviews, 2005. 6(1): p. 20-7.
Cagney, M., C. Macintyre, and P. Macintyre, Childhood asthma diagnosis
and use of asthma medication [Electronic version]. Australian Family
Physician, 2005. 34(3): p. 193-196.
Robertson, C.F., M.F. Daltori, J.K. Peat, M.M. Baby, A. Bauman, J.D.
Kennedy, and L.I. Landau, Asthma and other atopic diseases in Australian
children. [Electronic Version]. Medical Journal of Australia, 1998. 168(9): p.
434-8.
Australian Bureau of Statistics, National Health Survey: Summary of Results,
Australia. 2004-05, Canberra: Australian Bureau of Statistics. Cat no. 4364.0.
Stanford, R., T. McLaughlin, and L.J. Okamoto, The Cost ofAsthma in the
Emergency Department and Hospital. [Electronic Version]. Am. J. Respir.
Crit. Care Med., 1999. 160(1): p. 211-215.
Anonymous, New South Wales Child Health Survey 2001. New South Wales
Public Health Bulletin, 2002. 13(suppl 3): p. 34-36.
Peat, J.K., R.H. Van Den Berg, W.F. Green, C.M. Mellis, S.R. Leeder, and
A.J. Woolcock, Changing prevalence of asthma in Australian children.
[Electronic version]. British Medical Journal, 1994. 308: p. 1591-6.
Lozano, P., S.D. Sullivan, D.H. Smith, and K.B. Weiss, The economic burden
of asthma in US children: estimates from the National Medical Expenditure
Survey. [Electronic Version]. Journal of Allergy & Clinical Immunology,
1999. 104(5): p. 957-63.
Diette, G.B., L. Markson, E.A. Skinner, T.T.H. Nguyen, P. Algatt-Bergstrom,
and A.W. Wu, Nocturnal Asthma in Children Affects School Attendance,
School Performance, and Parents' Work Attendance. Arch Pediatr Adolesc
Med,2000. 154(9):p. 923-928.
Amado, M.C. and J.M. Portnoy, Recent advances in asthma management.
Missouri Medicine, 2006. 103(1): p. 60-4.
Gauld, L., G. Nixon, S. Sheridan, C. Robertson, and D. Hill, House dust mite
prevention measures are not effective in reducing house mite load, clinical
asthma or laboratory markers in chronic childhood asthma. Respirology,
2006. 11 (S2): p. A24.
Gibson, P.G., Simpson, J.L., Inflammatory Mediators ofAsthma in Children,
in Childhood Asthma. 2006, New York: Taylor & Francis. p. 287-301.
Galbrath, A., S. Bullock, and E. Manias, Fundamentals ofPharmacology: 4th
Edition. 2004: Pearson Education Australia.

78

82.
83.
84.

85.
86.

87.

88.

89.
90.

91.

92.

93.

94.

95.

96.

97.

Rees, J. and J. Price, ABC of asthma. Asthma in children: Treatment.
[Electronic version]. British Medical Journal, 1995. 310: p. 1522-7.
University of Michigan Health System, UMHS Asthma: Guidelines for
Clinical Care. 2000, University ofMichigan. p. 1-14.
Chapman, K.R., P. Patel, A.D. D'Urzo, M. Alexander, S. Mehra, C.
Oedekoven, R. Engelstatter, and L.P. Boulet, Maintenance of asthma control
by once-daily inhaled ciclesonide in adults with persistent asthma [Electronic
version]. Allergy, 2005. 60(3): p. 330-7.
Barnes, P.J. and I. Adcock, Anti-inflammatory actions of steroids: molecular
mechanisms. Trends in Pharmacological Sciences, 1993. 14(12): p. 436-41.
Leung, D.Y. and J.W. Bloom, Update on glucocorticoid action and
resistance [Electronic version]. Journal of Allergy & Clinical Immunology,
2003. 111(1): p. 13-22.
Umland, S.P., R.P. Schleimer, and S.L. Johnston, Review of the Molecular
and Cellular Mechanisms ofAction of Glucocorticoids for Use in Asthma.
[Electronic version}. Pulmonary Pharmacology & Therapeutics, 2002. 15: p.
35-50.
Coghlan, D. and C. Powell, Treatment of childhood asthma: how do the
available options compare? {Electronic version]. Paediatric Drugs, 2003.
5(10): p. 685-98.
Pedersen, S. and P. O'Byrne, A comparison of the efficacy and safety of
inhaled corticosteroids in asthma. Allergy, 1997. 52(S39): p. 1-34.
Adams, R.J., A. Fuhlbrigge, J.A. Finkelstein, P. Lozano, J.M. Livingston,
K.B. Weiss, and S.T. Weiss, Impact ofInhaled Antiinflammatory Therapy on
Hospitalization and Emergency Department Visits for Children With Asthma.
Pediatrics, 2001. 107(4): p. 706-711.
Dempsey, O.J., M. Humphreys, W.J. Coutie, and B.J. Lipworth, Relative lung
delivery offluticasone propionate via large volume spacer or nebuliser in
healthy volunteers [Electronic version]. European Journal of Clinical
Pharmacology, 2001. 57(9): p. 637-41.
Belvisi, M.G. and D.J. Hele, Soft steroids: a new approach to the treatment of
inflammatory airways diseases [Electronic version]. Pulmonary
Pharmacology & Therapeutics, 2003. 16(6): p. 321-325.
Szefler, S., S. Rohatagi, J. Williams, M. Lloyd, S. Kundu, and D. Banerji,
Ciclesonide, a novel inhaled steroid, does not affect hypothalamic-pituitaryadrenal axis function in patients with moderate-to-severe persistent asthrna.
[Electronic version]. Chest, 2005. 128(3): p. 1104-14.
Larsen, B.B., L.P. Nielsen, R. Engelstatter, V. Steinijans, and R. Dahl, Effect
of ciclesonide on allergen challenge in subjects with bronchial asthma
[Electronic version]. Allergy, 2003. 58(3): p. 207-12.
Thorsson, L., S. Edsbacker, A. Kallen, and C.G. Lofdahl, Pharmacokinetics
and systemic activity offluticasone via Diskus and pMDL and of budesonide
via Turbuhaler. British Journal of Clinical Pharmacology, 2001. 52(5): p.
529-38.
Roux, C., S. Kolta, J.L. Desfougeres, P. Minini, and E. Bidat, Long-term
safety offluticasone propionate and nedocromil sodium on bone in children
with asthma. [Electronic version]. Pediatrics, 2003. 111(6 Pt 1).
Saha, M.T., P. Laippala, and H.L. Lenko, Clinical observations on catch-up
growth in asthmatic children following withdrawal of inhaled
glucocorticosteroids. Pediatric Pulmonology, 1998. 26(4): p. 292-4.

79

98.

99.

100.
101.
102.
103.

104.

105.

106.

107.
108.

109.

110.

111.

112.

Silverstein, M.D., J.W. Yunginger, C.E. Reed, T. Petterson, D. Zimmerman,
J.T. Li, and W.M. O'Fallon, Attained adult height after childhood asthma:
effect ofglucocorticoid therapy. [Electronic version]. Journal of Allergy &
Clinical Immunology, 1997. 99(4): p. 466-74.
Van Bever, H.P., K.N. Desager, N. Lijssens, J.J. Weyler, and M.V. Du Caju,
Does treatment of asthmatic children with inhaled corticosteroids affect their
adult height? [Electronic version]. Pediatric Pulmonology, 1999. 27(6): p.
369-75.
Balfour-Lynn, L., Growth and childhood asthma. Archives of Disease in
Childhood, 1986. 61(11): p. 1049-55.
Martin, A.J., L.I. Landau, and P.D. Phelan, The effect on growth of childhood
asthma. Acta Paediatrica Scandinavica, 1981. 70(5): p. 683-8.
Pedersen, S., Long-term outcomes in paediatric asthma. [Electronic version].
Allergy, 2002. 57(s74): p. 58-74.
Boccuti, L., M. Celano, R.J. Geller, and K.M. Phillips, Development of a
scale to measure children's metered-dose inhaler and spacer technique
[Electronic version]. Annals of Allergy, Asthma, & Immunology, 1996.
77(3): p. 217-21.
O'Callaghan, C. and P.W. Barry, How to choose delivery devices for asthma.
[Electronic version]. Archives of Disease in Childhood, 2000. 82(3): p. 1857.
Ross, D.L. and R.K. Schultz, Effect ofinhalationfow rate on the dosing
characteristics of dry powder inhaler (DPJ) and metered dose inhaler (MDI)
products. Journal of Aerosol Medicine, 1996. 9: p. 215-26.
Robertson, C.F., M.A. Norden, D.A. Fitzgerald, F.L. Connor, P.P. Van
Asperen, P.J. Cooper, P.W. Francis, and H.D. Allen, Treatment of acute
asthma: salbutamol via jet nebuliser vs spacer and metered dose inhaler.
[Electronic version]. Journal of Paediatrics & Child Health, 1998. 34(2): p.
142-6.
Powell, C. V. and M.L. Everard, Treatment of childhood asthma. Options and
rationale for inhaled therapy. Drugs, 1998. 55(2): p. 237-52.
Lin, Y.Z. and K.H. Hsieh, Metered dose inhaler and nebuliser in acute
asthma. [Electronic version]. Archives of Disease in Childhood, 1995. 72(3):
p. 214-8.
Lewis, R.A. and S.S. Flemming, Fractional depositionfrom a jet nebuliser:
How it differs from a metered dose inhaler. British Journal Disease Chest,
1985. 79: p. 361-367.
Turner, M.O., A. Gafni, D. Swan, and J.M. Fitzgerald, A review and
economic evaluation ofbronchodilator delivery methods in hospitalized
patients. [Electronic version]. Archives oflnternal Medicine, 1996. 156(18):
p. 2113-8.
Newman, S.P., F. Moren, D. Pavia, F. Little, and S.W. Clarke, Deposition of
pressurized suspension aerosols inhaled through extension devices. American
Review of Respiratory Disease, 19 81. 124(3): p. 31 7-20.
Deerojanawong, J., W. Manuyakorn, N. Prapphal, C. Harmuthakorn, S.
Sritippayawan, and R. Samransamruajkit, Randomized controlled trial of
salbutamol aerosol therapy via metered dose inhaler-spacer vs. jet nebulizer
in young children with wheezing [Electronic version]. Pediatric
Pulmonology, 2005. 39(5): p. 466-72.

80

113.

114.

115.

116.
117.

118.

119.

120.

121.

122.

123.
124.

125.

126.

Leversha, A.M., S.G. Campanella, R.P. Aickin, and M.I. Asher, Costs and
effectiveness ofspacer versus nebulizer in young children with moderate and
severe acute asthma. [Electronic version]. Journal of Pediatrics, 2000.
136(4): p. 497-502.
Kerem, E., H. Levison, S. Schuh, H. O'Brodovich, J. Reisman, L. Bentur, and
G.J. Canny, Efficacy of albuterol administered by nebulizer versus spacer
device in children with acute asthma. Journal ofPediatrics, 1993. 123(2): p.
313-7.
Chou, K.J., S.J. Cunningham, and E.F. Crain, Metered-dose inhalers with
spacers vs nebulizers for pediatric asthma.[erratum appears in Arch Pediatr
Adolesc Med 1995 May;l49(5):545]. Archives ofPediatrics & Adolescent
Medicine, 1995. 149(2): p. 201-5.
O'Callaghan, C., Delivery Systems: The Science. [Electronic version].
Pediatric Pulmonology Supplement, 1997. 15: p. 51-4.
Everard, M.L., A.R. Clark, and A.D. Milner, Drug delivery for holding
chambers with attached face mask. Archives of Disease in Childhood, 1992.
67: p. 580-585.
Barry, P.W. and C. O'Callaghan, Multiple actuations ofsalbutamol MDI into
a spacer device reduce the amount of drug recovered from the respirable
range [Electronic version]. European Respiratory Journal, 1994. 7: p. 17071709.
Wildhaber, J.H., S.G. Devadason, E. Eber, M.J. Hayden, M.L. Everard, Q.A.
Summers, and P.N. Le Souef, Effects of Electrostatic Charge, Flow, Delay
and Multiple Actuations on the In Vitro Delivery of Salbutamol from
Different Small Volume Spacers for Infants. [Electronic version]. Thorax,
1996. 51(10): p. 985-988.
Pierart, F., J.H. Wildhaber, I. Vrancken, S.G. Devadason, and P.N. Le Souef,
Washing plastic spacers in household detergent reduces electrostatic charge
and greatly improves delivery. [Electronic version]. European Respiratory
Journal, 1999. 13(3): p. 673-8.
Wildhaber, J.H., H.M. Janssens, F. Pierart, N.D. Dore, S.G. Devadason, and
P.N. LeSouef, High-percentage lung delivery in children from detergenttreated spacers. [Electronic version]. Pediatric Pulmonology, 2000. 29(5): p.
389-93.
Bisgaard, H., A metal aerosol holding chamber devised for young children
with asthma [Electronic version]. European Respiratory Journal, 1995. 8(5):
p. 856-60.
Nikander, K.D., J., Breathing patterns. Eur Respir Rev, 2000. 10(76): p. 576579.
Vella, C. and V. Grech, Assessment of use of spacer devices for inhaled drug
delivery to asthmatic children. [Electronic version]. Pediatric Allergy and
Immunology, 2005. 16(3): p. 258-261.
Van Beerendonk, I., I. Mesters, A.N. Mudde, and T.D. Tan, Assessment of the
inhalation technique in outpatients with asthma or chronic obstructive
pulmonary disease using a metered-dose inhaler or dry powder device.
Journal of Asthma, 1998. 35(3): p. 273-9.
VanDer Palen, J., J.J. Klein, A.H. Kerkhoff, and C.L. Van Herwaarden,
Evaluation of the effectiveness offour different inhalers in patients with
chronic obstructive pulmonary disease. Thorax, 1995. 50(11): p. 1183-1187.

81

127.

128.

129.

130.

131.
132.

133.

134.

135.

136.

137.
138.
139.

140.

141,.
142.

Manzella, B.A., C.M. Brooks, J.M. Richards, Jr., R.A. Windsor, S. Soong,
and W.C. Bailey, Assessing the use of metered dose inhalers by adults with
asthma. Journal of Asthma, 1989. 26(4): p. 223-30.
Goodman, D.E., E. Israel, M. Rosenberg, R. Johnston, S.T. Weiss, and J.M.
Drazen, The influence of age, diagnosis, and gender on proper use of
metered-dose inhalers. Am J Respir Crit Care Med., 1994. 150(5 Pt 1): p.
1256-61.
Pedersen, S., L. Frost, and T. Arnfred, Errors in inhalation technique and
efficiency in inhaler use in asthmatic children. Allergy, 1986. 41(2): p. 11824.
Baciewicz, A.M. and K.S. Kyllonen, Aerosol inhaler technique in children
with asthma. American Journal ofHospital Pharmacy, 1989. 46(12): p. 25101.
Rand, C.S., Adherence to asthma therapy in the preschool child. Allergy,
2002. 57(s74): p. 48-57.
Abley, C., Teaching elderly patients how to use inhalers. A study to evaluate
an education programme on inhaler technique, for elderly patients. Journal
of Advanced Nursing, 1997. 25(4): p. 699-708.
Basheti, I.A., H.K. Reddel, C.L. Armour, and S.Z. Bosnic-Anticevich,
Counseling About turbuhaler Technique: Needs Assessment and Effective
Strategies for Community Pharmacists [Electronic version}. Respiratory
Care, 2005. 50(5): p. 617-23.
Nimmo, C., D. Chen, S. Martinusen, T. Ustad, and D. Ostrow, Assessment of
patient acceptance and inhalation technique of a pressurized aerosol inhaler
and two breath-actuated devices. The Annals of Pharmacotherapy, 1993.
27(7-8): p. 922-927.
Rydman, R.J., K. Sonenthal, L. Tadimeti, N. Butki, and M.F. McDermott,
Evaluating the outcome of two teaching methods of breath actuated inhaler in
an inner city asthma clinic. Journal ofMedical Systems, 1999. 23(5): p. 34956.
Hendriks, H.J.E., P.C. Overberg, H. Bracke, and N.A. Vermue, Handling of a
spacer (Babyhaler) for inhalation therapy in 0- to3-year old children.
Journal Asthma. Journal of Asthma, 1998. 35: p. 297-304.
Shim, C. and M.H. Williams, Jr., The Adequacy ofInhalation ofAerosol from
Canister Nebulizers. American Journal of Medicine, 1980. 69(6): p. 891-4.
Clark, N.M. and M.R. Partridge, Sirengthening asthma education to enhance
disease control [Electronic version]. Chest, 2006. 121(5): p. 1661-9.
Clark, N.M., M. Gong; M.A. Schork, N. Kaciroti, D. Evans, D. Roloff, M.
Hurwitz, L.A. Maiman, and R.B. Mellins, Long-term effects of asthma
education for physicians on patient satisfaction and use of health services
[Electronic version}. European Respiratory Journal, 2000. 16(1): p. 15-21.
Sawyer, S.M. and J. Pardy, Bridging the Gap Between Doctor's and Patients'
Expectations ofAsthma Management. Journal of Asthma, 2003. 40(2): p.
131-138.
Everard, M.L., Regimen and device compliance: key factors in determining
therapeutic outcomes. Journal of Aerosol Medicine, 2006. 19(1): p. 67-73.
Milgram, H., B. Bender, L. Ackerson, P. Bowry, B. Smith, and C. Rand,
Noncompliance and treatment failure in children with asthma. Journal of
Allergy & Clinical Immunology, 1996. 98(6): p. 1051-1057.

82

143.
144.

145.

146.

147.

148.

Paton, J.Y., Asthma Education: Translating Knowledge into Action, in
Childhood Asthma. 2006, New York: Taylor & Francis. p. 333-354.
Everard, M.L., S.G. Devadason, Q.A. Summers, and P.N. Le Souef, Factors
affecting total and "respirable" dose delivered by a salbutamol metered dose
inhaler. Thorax, 1995. 50(7): p. 746-9.
Wilson, S.R., P. Scamagas, D.F. German, G.W. Hughes, S. Lulla, S. Coss, L.
Chardon, R.G. Thomas, N. Starr-Schneidkraut, F.B. Stancavage, and et al., A
controlled trial of two forms ofself-management education for adults with
asthma. Am J Med, 1993. 94(6): p. 564-76.
Pedersen, S. and P.A. Ostergaard, Nasal inhalation as a cause of inefficient
pulmonal aerosol inhalation technique in children. Allergy, 1983. 38(3): p.
191-4.
Wang, X., D.W. Dockery, D. Wypij, M.E. Fay, and B.G. Ferris, Jr.,
Pulmonary function between 6 and 18 years of age. Pediatr Pulmonol., 1993.
15(2): p. 75-88.
Sherrill, D.L., A. Camilli, and M.D. Lebowitz, On the temporal relationships
between lung function and somatic growth. Am Rev Respir Dis., 1989.
140(3): p. 638-44.

83

APPENDIX I
INFORMATION LETTER AND CONSENT FORM

84

Womevis:)
C.\-;\dYeVI'S
Heallh Service

Parent Information Sheet

Effect of a paediatric incentive spacer and reinforcement of
inhalation technique training on drug delivery to preschool children
in both clinical and domiciliary settings.
Randomisation Number:
Date of Birth:

Subject Initials: _ _

___ _______ / _________
/

Introduction:
In addition to your participation in the Funhaler study we would like to invite your child to
take part in a filter study that will assess the amount of medication he/she is inhaling. One
component of the study will be conducted in the clinic and the other component will take
place in your home. We will then compare the amount of medication delivered in a clinic
versus a home setting. The reason for thjs study is to investigate whether the dose of asthma
medication received by children is more variable when used daily in the home setting than
when used in the hospital clinic setting. This study will involve a sub-group of 40 children
from the Funhaler study.

Overview:
This information sheet provides a written overview of the study as well as an explanation of
the procedures involved and will also be verbally discussed with you to ensure your
complete understanding. Once you feel confident that you understand the study, and if you
agree to allow your child to take part, you will be asked to sign a consent form.

Before you learn more about this study, it is important to know that:
Your child's participation is entirely voluntary.
You can continue to participate in the Fun haler Study without taking
part in this filter study.
You can withdraw your child from the study (through verbal
notification) at any time without compromising his/her routine medical
care in any way.

Background:
Variability in drug delivery due to incorrect inhaler device technique and resistance to
treatment is a common problem in paediatric asthma. The effect of clinic-based technique
training in young children and their parents has not been extensively researched previously.
Assessment of drug delivery in a clinical setting and a home setting will verify if clinical
training improves technique and if this improvement correlated with non-variable drug
delivery in the home. The Funhaler™ was developed in an attempt to alleviate children's fear
of using standard asthma delivery devices. The devices currently available are difficult to use
with small children and infants and therefore inefficient. The purpose of the Funhaler™ is to
help overcome these difficulties by motivating the child to inhale willingly and effectively
by the use of breath-driven toys attached to the device, such as whistles and spinning disks.
This study will.build on previous research done at Princess Margaret Hospital.
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Procedures:
In the clinic visit you and your child will be asked to demonstrate your drug delivery
technique pre and post training. During the procedure a filter will be placed between the
spacer and your child's mouth so he/she will not receive any drug. The procedure will be
videoed taped for qualitative analysis later. The video recordings will be stored electronically
on a secure network folder which is password protected and will only be available to
the investigator and supervisors. As part of the pre training analysis your
administration technique and your child's breathing technique will be assessed and
any errors will be corrected. A 1 minute training video will also be shown. To assess any
improvement a post training analysis will then take place.

Following this visit, 14 filters will be dispensed for the home filter study. For a week, you
will be asked to give your child their normal prescribed medication first and then repeat the
procedure with a filter. The filter will be inserted in between the spacer and your child's
mouth. You will continue to give your child their normal asthma medication, and he/she will
not inhale any additional drug when using the filters. You will be shown how to store the
filters until we can arrange to collect them.

Benefits associated with this study:
By taking part in this study, your child will additionally support the development of a
new form of asthma medication delivery from which he/she and other patients might
benefit in the future.

Risks associated with this Study:
There are no risks involved. Your child's normal medication will not be interfered with in
anyw~y.

Confidentiality:
Your child's research records will be confidential to the extent permitted by law. Your child
will be identified by a code, and any personal information from his/her records will not be
released. The information will always be treated confidentially and securely stored and you
or your child will not be personally identified in any publications about this study. However,
representatives of the ethics committee and from the regulatory bodies may check that the
information collected
during the study is accurate.

Queries

If you have any questions or require any further information about this study or your child's
rights, please contact Jasminka Murdzoska on 9340 8452. If you have any complaints
regarding the conduct of the study, please contact the Executive Director of Medical
Services at Princess Margaret Hospital on 9340 8222.
Thank you for taking the time to find out more about this study.
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~FORM OF CONSENT

Subject Initials: _ _ _ _ _ _ _ _ _ _ __

Randomisation

Number:

I, ......................................................................................... have had the study clearly explained
tome
(Given Names)
(Surname)
and I have read and understood the information sheet explaining the study entitled:
Effect of a paediatric incentive spacer and reinforcement of inhalation technique training on
drug delivery to preschool children in both clinical and domiciliary settings.
Any questions I have asked have been answered to my satisfaction.
I agree to allow the participation in this study of

Daughter

I

Son
(Full name of participant)

(please circle)

I understand I may decline to enter or withdraw my child from the study at any stage and
without interfering with routine medical care. I have been made aware of my right to access
and request correction of my child's personal data. I acknowledge that I have received a copy
of this form for future reference.
I agree that research data gathered from the results of this study may be published, provided
that my child is not identified. I also give permission for the study investigators, independent
auditors and other regulatory authorities if required to have access to my child's medical
records, in the knowledge that all information will be treated as strictly confidential.

Signature: .............................................................................. .

Dated: ............. day of .................................................. 20 ........ ..

I, .................................................................................................................. .
(Investigator's full name and signature)
have explained the nature, demands and foreseeable risks and benefits of the study to the
person named above who stated he/she understood the same and have witnessed the
completion of the consent form.
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APPENDIX II

TECHNIQUE EVALUATION CHECK-LIST
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TECHNIQUE EVALUATION
PRE-TRAINING EVALUATION

Time: - - - -

Action
Shaking pMDI before each actuation
(O=no, 1=sometimes, 2=always)
Appropriate insertion of pMDI into spacer
(O=no, 1=yes)
Placement of spacer in child's mouth
(O=no, 1=yes)
Single dose actuation
(O=no, 1=yes)
Five tidal breaths through spacer
(O=child refuses, 1=uneven/fast breathing, 2=s/ow even
breathing)
Actuation of appropriate number of doses
(O=no, 1=yes)
Detachment of spacer from mouth after actuation
(O=often, 1=sometimes, 2=never)
Extent of struggling
(O=vigorous, 1=slight, 2=none)

Score

TOTAL SCORE

COMMENTS: _ _ _ _ _ _ _ _ _ _ _ _ _ _ __

Signature/Date: _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __
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POST-TRAINING EVALUATION

Time: _ _ _ __

Was the training video shown?
If yes, which video?
Aerochamber

DoNo
01 Funhaler

Action
Shaking pMDI before each actuation
(O=no, 1=sometimes, 2=always)
Appropriate insertion of pMDI into spacer
(O=no, 1=yes)
Placement of spacer in child's mouth
(O=no, 1=yes)
Single dose actuation
(O=no, 1=yes)
Five tidal breaths through spacer
(O=child refuses, 1=uneven/fast breathing, 2=slow even
breathing)
Actuation of appropriate number of doses
(O=no, 1=yes)
Detachment of spacer from mouth after actuation
(O=often, 1=sometimes, 2=never)
Extent of struggling
(O=vigorous, 1=slight, 2=none)

Score

TOTAL SCORE

COMMENTS: _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __

Signature/Date: _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __
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